<SEC-DOCUMENT>0001193125-22-206851.txt : 20220729
<SEC-HEADER>0001193125-22-206851.hdr.sgml : 20220729
<ACCEPTANCE-DATETIME>20220729171810
ACCESSION NUMBER:		0001193125-22-206851
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		24
CONFORMED PERIOD OF REPORT:	20220727
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220729
DATE AS OF CHANGE:		20220729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		221121879

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d342123d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20220727" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-07-27_to_2022-07-27">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-07-27_to_2022-07-27">0001062822</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="lxrx-20220727.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-07-27_to_2022-07-27"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-27</xbrli:startDate> <xbrli:endDate>2022-07-27</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-07-27_to_2022-07-27">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt:datemonthdayyearen">July 27, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-07-27_to_2022-07-27">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-07-27_to_2022-07-27">000-30111</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-07-27_to_2022-07-27">76-0474169</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction of<br />incorporation or organization)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification Number)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-07-27_to_2022-07-27">2445 Technology Forest Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-07-27_to_2022-07-27">11<sup style="font-size:75%; vertical-align:top">th</sup> Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-07-27_to_2022-07-27">The Woodlands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-07-27_to_2022-07-27">77381</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices and Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-07-27_to_2022-07-27">(281)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-07-27_to_2022-07-27">863-3000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-07-27_to_2022-07-27">Common stock, par value $0.001</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-07-27_to_2022-07-27">LXRX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-07-27_to_2022-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Underwriting Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On July&#160;27, 2022, Lexicon Pharmaceuticals, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into an Underwriting Agreement (the &#8220;<span style="text-decoration:underline">Underwriting Agreement</span>&#8221;) with Citigroup Global Markets Inc. and Piper Sandler&#160;&amp; Co., as representatives of the several underwriters named therein (the &#8220;<span style="text-decoration:underline">Underwriters</span>&#8221;), relating to a public offering (the &#8220;<span style="text-decoration:underline">Offering</span>&#8221;) of 16,843,600 shares (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (&#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The price to the public for the Shares in the Offering was $2.50 per Share. In addition, under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,526,540 shares of Common Stock (the &#8220;<span style="text-decoration:underline">Option Shares</span>&#8221;) at the same price per share as the Shares. The net proceeds to the Company from the Offering are expected to be approximately $39.3&#160;million (or approximately $45.2&#160;million if the Underwriters exercise their option to purchase the Option Shares in full), in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Underwriting Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing, obligations of the parties and termination provisions. Additionally, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the&#160;Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act</span>&#8221;). The Company has also agreed with the Underwriters not to offer or sell any shares of its Common Stock (or securities convertible into or exchangeable for Common Stock), subject to certain exceptions, for a period of 60 days after the date of the Underwriting Agreement without the prior written consent of Citigroup Global Markets Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Offering was made pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-258564)</span> (the &#8220;<span style="text-decoration:underline">Registration Statement</span>&#8221;), declared effective by the Securities and Exchange Commission on September&#160;14, 2021, and a related prospectus included in the Registration Statement, as supplemented by a preliminary prospectus supplement dated July 27, 2022 and a final prospectus supplement dated July 27, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing summary of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is attached to this Current Report on Form <span style="white-space:nowrap">8-K</span> (this &#8220;<span style="text-decoration:underline">Current Report</span>&#8221;) as Exhibit 1.1, and which is incorporated herein by reference. Vinson&#160;&amp; Elkins L.L.P., counsel to the Company, delivered an opinion as to the legality of the issuance and sale of the Shares in the Offering, a copy of which is attached hereto as Exhibit 5.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purchase Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On July&#160;27, 2022, the Company entered into (i) a purchase agreement (the &#8220;<span style="text-decoration:underline">Artal Purchase Agreement</span>&#8221;) with Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P. (&#8220;<span style="text-decoration:underline">Invus</span>&#8221;), Mr.&#160;Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. and (ii) a purchase agreement with Invus US Partners LLC (the &#8220;<span style="text-decoration:underline">Invus Purchase Agreement</span>&#8221; and together with the Artal Purchase Agreement, the &#8220;<span style="text-decoration:underline">Purchase Agreements</span>&#8221;) for purposes of waiving certain preemptive rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the Purchase Agreements, two affiliates of Invus (the &#8220;<span style="text-decoration:underline">Private Placement Purchasers</span>&#8221;) have agreed to purchase, and the Company has agreed to issue to the Private Placement Purchasers on the closing date of the Offering, 17,156,400 shares of Common Stock at a price per share equal to the price per share to the public in the Offering (the &#8220;<span style="text-decoration:underline">Private Placement</span>&#8221;). The total purchase price shall be equal to approximately $42.9&#160;million. The Private Placement Purchasers will have the option to purchase, on a pro rata basis, up to an additional 2,573,460 shares of Common Stock to the extent the Underwriters exercise their option to purchase the Option Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Purchase Agreements incorporate the representations and warranties and covenants made by the Company in the Underwriting Agreement for the benefit of the Private Placement Purchasers and certain of their affiliates. It also contains customary conditions to closing, obligations of the parties and termination provisions. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Artal Purchase Agreement and the Invus Purchase Agreement are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report and are incorporated herein by reference. The description of the Purchase Agreements in this Current Report is a summary and is qualified in its entirety by the terms of the Purchase Agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"><span style="font-style:italic">Relationships </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">After the Offering and the Private Placement, Invus and its affiliates will hold approximately the same percentage of the Company&#8217;s outstanding Common Stock as they did before the Offering and the Private Placement. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information set forth under &#8220;Purchase Agreements&#8221; in Item 1.01 of this Current Report is hereby incorporated in this Item 3.02 by reference. The Private Placement will be taken in reliance upon the exemption from the registration requirements of the Securities Act provided by Section&#160;4(a)(2) thereof. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On July&#160;27, 2022, the Company issued a press release announcing the launch of the Offering. A copy of the press release relating to the launch of the Offering is furnished as Exhibit 99.1 to this Current Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On July&#160;28, 2022, the Company issued a press release announcing the pricing of the Offering. A copy of the press release relating to the pricing of the Offering is furnished as Exhibit 99.2 to this Current Report. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">In accordance with General Instruction B.2 of Form <span style="white-space:nowrap">8-K,</span> the information furnished pursuant to this Item 7.01 or Exhibits 99.1 and 99.2 shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the&#160;Securities Act&#160;or the&#160;Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information furnished pursuant to Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely to satisfy the requirements of&#160;Regulation FD. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On July&#160;27, 2022, the Company issued a press release announcing that the U.S. Food and Drug Administration accepted for review and filed our New Drug Application for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. A copy of the press release relating to the announcement is attached hereto as Exhibit 99.3 and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:6%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;1.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex11.htm">Underwriting Agreement, dated as of July&#160;27, 2022, by and among Lexicon Pharmaceuticals, Inc. and Citigroup Global Markets Inc. and Piper Sandler&#160;&amp; Co., as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;5.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex51.htm">Opinion of Vinson&#160;&amp; Elkins L.L.P. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex101.htm">Purchase Agreement, dated as of July&#160;27, 2022, among Lexicon Pharmaceuticals, Inc. and Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex102.htm">Purchase Agreement, dated as of July&#160;27, 2022, among Lexicon Pharmaceuticals, Inc. and Invus US Partners LLC. </a></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex51.htm">Consent of Vinson&#160;&amp; Elkins L.L.P. (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex991.htm">Press Release, dated July&#160;27, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex992.htm">Press Release, dated July&#160;28, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d342123dex993.htm">Press Release, dated July&#160;27, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"><span style="white-space:nowrap">EX-104</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signatures </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">Lexicon Pharmaceuticals, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: July&#160;29, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian T. Crum</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Brian T. Crum</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">Senior Vice President and General Counsel</span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d342123dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16,843,600 Shares </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common Stock
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">($0.001 par value) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July&nbsp;27, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the
several Underwriters </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Citigroup Global Markets Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">388 Greenwich Street </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New York, New York 10013 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Piper Sandler&nbsp;&amp; Co. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">800 Nicollet Mall </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Minneapolis, Minnesota 55402 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals,
Inc., a corporation organized under the laws of Delaware (the &#147;<U>Company</U>&#148;), proposes to sell to the several underwriters named in <U>Schedule II</U> hereto (the &#147;<U>Underwriters</U>&#148;), for whom you (the
&#147;<U>Representatives</U>&#148;) are acting as representatives, the number of shares of common stock, $0.001 par value (&#147;<U>Common Stock</U>&#148;) of the Company set forth in <U>Schedule I</U> hereto (the &#147;<U>Shares</U>&#148;) (said
Shares to be issued and sold by the Company being hereinafter called the &#147;<U>Underwritten Securities</U>&#148;). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock
set forth in <U>Schedule I</U> hereto (the &#147;<U>Option Securities</U>;&#148; the Option Securities, together with the Underwritten Securities, being hereinafter called the &#147;<U>Securities</U>&#148;). To the extent there are no additional
Underwriters listed on <U>Schedule II</U> other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this underwriting agreement (this &#147;<U>Agreement</U>&#148;), the &#147;<U>Registration Statement</U>&#148; means the
registration statement referred to in paragraph 1(a) hereof, including the exhibits, schedules and financial statements and any prospectus supplement relating to the Securities that is filed with the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the &#147;<U>Securities Act</U>&#148;) and deemed part of such registration statement pursuant to
Rule 430B under the Securities Act, as amended on each Effective Date, and, in the event any post-effective amendment thereto or any registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act (a
&#147;<U>Rule 462(b) Registration Statement</U>&#148;)<B> </B>becomes effective prior to the Closing Date (as defined in Section&nbsp;3 hereof), shall also mean such registration statement as so amended or such Rule 462(b) Registration Statement, as
the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case may be; the &#147;<U>Effective Date</U>&#148; means each date and time that the Registration Statement, any post-effective amendment or amendments thereto or any Rule 462(b) Registration
Statement became or becomes effective; the &#147;<U>Base Prospectus</U>&#148; means the base prospectus referred to in paragraph 1(a) hereof contained in the Registration Statement at the date and time that this Agreement is executed and delivered
by the parties hereto (the &#147;<U>Execution Time</U>&#148;); the &#147;<U>Preliminary Prospectus Supplement</U>&#148; means any preliminary prospectus supplement to the Base Prospectus referred to in paragraph 1(a) hereof which is used prior to
the filing of the Final Prospectus Supplement, together with the Base Prospectus; and the &#147;<U>Final Prospectus Supplement</U>&#148; means the prospectus supplement relating to the Securities that is first filed pursuant to Rule 424(b) under the
Securities Act (&#147;<U>Rule 424(b)</U>&#148;) after the Execution Time, together with the Base Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference herein to the
Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> which were filed under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the &#147;<U>Exchange Act</U>&#148;) on or before the Effective Date of the
Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or
&#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange
Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the &#147;<U>Pricing Disclosure Package</U>&#148; shall mean (i)&nbsp;the Base Prospectus, (ii)&nbsp;the
Preliminary Prospectus Supplement used most recently prior to the Execution Time, (iii)&nbsp;any issuer free writing prospectus, as defined in Rule 433 under the Securities Act (an &#147;<U>Issuer Free Writing Prospectus</U>&#148;), identified in
<U>Schedule III</U> hereto, and (iv)&nbsp;any other free writing prospectus, as defined in Rule 405 under the Securities Act (a &#147;<U>Free Writing Prospectus</U>&#148;), that the parties hereto shall hereafter expressly agree in writing to treat
as part of the Pricing Disclosure Package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Representations and Warranties</U>. The Company represents and warrants to, and agrees
with, each Underwriter as set forth below in this Section&nbsp;1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act and has prepared and filed with the SEC a shelf registration statement, as defined in Rule 405 (file number <FONT STYLE="white-space:nowrap">333-258564)</FONT> on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> including a related Base Prospectus, for registration under the Securities Act of the offering and sale of the Shares. The Company may have filed one or more amendments thereto, including any Preliminary
Prospectus Supplement, each of which has previously been furnished to you and has become effective upon filing. The Company will next file with the SEC a Final Prospectus Supplement relating to the Shares in accordance with Rule 424(b). As filed,
such Final Prospectus Supplement shall contain all information required by the Securities Act and the rules thereunder and, except to the extent the Representatives shall agree in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
writing to a modification, shall be in all substantive respects in the form furnished to you prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain only
such specific additional information and other changes (beyond that contained in the Base Prospectus and any Preliminary Prospectus Supplement) as the Company has advised you, prior to the Execution Time, will be included or made therein. The
Registration Statement, at the Execution Time, is effective and meets the requirements set forth in Rule 415(a)(1)(x). There is no order preventing or suspending the use of the Registration Statement, the Pricing Disclosure Package or the Final
Prospectus Supplement, and, to the knowledge of the Company, no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering has been initiated or threatened by the SEC and no notice
of objection of the SEC to the use of such Registration Statement pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary
Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> which were filed under the
Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference herein to the terms
&#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the
filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be
incorporated therein by reference. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On each Effective Date, the Registration Statement did, and when the Final
Prospectus Supplement is first filed in accordance with Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (and any amendment or supplement thereto) will, comply in all material respects with the applicable requirements of the
Securities Act and the Exchange Act and the respective rules thereunder; on each Effective Date, at the Execution Time, and on the Closing Date, the Registration Statement did not and will not contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the date of any filing pursuant to Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (together
with any amendment or supplement thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; <I>provided</I>, <I>however</I>, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Final Prospectus Supplement (or any amendment or supplement
thereto) in reliance upon and in conformity with information furnished in writing to the Company by the Underwriters specifically for inclusion in the Registration Statement or the Final Prospectus Supplement (or any amendment or supplement
thereto), it being understood and agreed that the only such information furnished by the Underwriters consists of the information described as such in Section&nbsp;8(b) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As of the Execution Time, the Pricing Disclosure Package, when taken
together as a whole with the pricing information set forth in <U>Schedule I</U> hereto, and each electronic road show, when taken together as a whole with the pricing information set forth in <U>Schedule I</U> hereto, does not, and as of the Closing
Date will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence
does not apply to statements in or omissions from the Pricing Disclosure Package based upon and in conformity with written information furnished to the Company by the Underwriters specifically for use therein, it being understood and agreed that the
only such information furnished by or on behalf of the Underwriters consists of the information described as such in Section&nbsp;8(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) (i) At the earliest time after the filing of the Registration Statement that the Company or another offering participant
made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii)&nbsp;as of the Execution Time (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an
Ineligible Issuer (as defined in Rule 405), without taking account of any determination by the SEC pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) or will pay such fee within the time
period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any of the Shares by
means of any &#147;prospectus&#148; (within the meaning of the Securities Act) or used any &#147;prospectus&#148; (within the meaning of the Securities Act) in connection with the offer or sale of the Shares, in each case other than the Registration
Statement, any Preliminary Prospectus Supplement and the Final Prospectus Supplement. The Company represents and agrees that it has not and, unless it obtains the prior consent of the Underwriters, it will not make any offer relating to the Shares
that would constitute an &#147;Issuer Free Writing Prospectus&#148; or that would otherwise constitute a &#147;Free Writing Prospectus&#148; other than any Permitted Free Writing Prospectus. Any such Free Writing Prospectus relating to the Shares
consented to by the Representatives is hereinafter referred to as a &#147;<U>Permitted Free Writing Prospectus</U>.&#148; The Company has complied and will comply in all material respects with the requirements of Rule 433 under the Securities Act
applicable to any Permitted Free Writing Prospectus, including timely filing with the SEC where required, legending and record keeping. Each Permitted Free Writing Prospectus does not conflict with the information contained in the Registration
Statement or the Pricing Disclosure Package did not and on the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <I>provided, however</I>, that the Company makes no representations or warranties as to the information contained in or omitted from such Permitted Free Writing Prospectus in reliance upon
and in conformity with information furnished in writing to the Company by the Underwriters specifically for inclusion in such Permitted Free Writing Prospectus, it being understood and agreed that the only such information furnished by the
Underwriters consists of the information described as such in Section&nbsp;8(b) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All statistical, demographic and market-related data included in the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent
the Company&#146;s good faith estimates that are made on the basis thereof. To the extent required, the Company has obtained the written consent for the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company has established and maintains &#147;disclosure controls and procedures&#148; (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is
made known to the Company&#146;s principal executive officer and its principal financial or accounting executive officer by others within those entities, within the time periods specified in the SEC&#146;s rules and forms; (ii)&nbsp;have been
evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of
the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over
financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) (i) The Company&#146;s authorized equity capitalization is as set forth in the Pricing Disclosure Package and the Final
Prospectus Supplement; (ii)&nbsp;the capital stock of the Company conforms in all respects to the description thereof contained in the Pricing Disclosure Package and the Final Prospectus Supplement; (iii)&nbsp;the outstanding shares of Common Stock
have been duly and validly authorized and issued and are fully paid and nonassessable; (iv)&nbsp;the Shares have been duly and validly authorized and, when issued and delivered to and paid for by the Underwriters pursuant to this Agreement, will be
fully paid and nonassessable; (v)&nbsp;the Securities in book-entry form are in valid and sufficient form; (vi)&nbsp;the holders of outstanding shares of capital stock of the Company are not entitled to preemptive or other rights to subscribe for
the Securities, except for any such rights as have been effectively waived or satisfied; and, (vii)&nbsp;except as set forth in the Pricing Disclosure Package and the Final Prospectus Supplement, no options, warrants or other rights to purchase,
agreements or other obligations to issue, or rights to convert any obligations into or exchange any securities for, shares of capital stock of or ownership interests in the Company are outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) There is no material agreement required to be described in the
Registration Statement or incorporated therein, or to be filed as an exhibit thereto, which is not described or filed as required (and the Preliminary Prospectus Supplement contains in all material respects the same description of the foregoing
matters contained in the Final Prospectus Supplement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Except as otherwise disclosed in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement, there are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering
contemplated by this Agreement, except for such rights as have been duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Subsequent to the respective dates as
of which information is given in the Registration Statement and the Final Prospectus Supplement: (i)&nbsp;there has been no material adverse change, or any development that could be reasonably expected to result in a material adverse change, in
(A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company
and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#147;<U>Material
Adverse Change</U>&#148;); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their
business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the
aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material
increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other
subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in
this Agreement includes the related notes thereto) filed with the SEC as a part of the Registration Statement, the Base Prospectus and the Final Prospectus Supplement, is (i)&nbsp;an independent registered public accounting firm as required by the
Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<U>PCAOB</U>&#148;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT
STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked
and who has not requested such registration to be withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The financial statements filed with the SEC as a part of the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement comply as to form in all material respects with the requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and
present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the
periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes
thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement fairly presents the information called
for in all material respects and has been prepared in accordance with the SEC&#146;s rules and guidelines applicable thereto in all material respects. No other financial statements or supporting schedules are required to be included in the
Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) The Company and each of its
subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific
authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets;
(iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is
taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement fairly presents the information called for in all material respects and is prepared in accordance with the SEC&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct
of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of
this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under
the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus Supplement. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All
of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the
Final Prospectus Supplement, are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any
corporation, association or other entity that would constitute a significant subsidiary as defined under Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> other than the subsidiaries listed
in Exhibit 21 to the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)
The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement under the caption &#147;Capitalization&#148; (other than for
subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Final Prospectus Supplement). The Common Stock (including the
Shares) conform in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. All of the issued and outstanding Common Stock have been duly authorized
and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common Stock was issued in violation of any preemptive rights, rights of first refusal or
other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible
into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) The Common Stock are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and are listed on the Nasdaq
Global Select Market (&#147;<U>Nasdaq</U>&#148;), and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from
Nasdaq, nor has the Company received any notification that the SEC or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance in all material respects with all applicable listing
requirements of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Neither the Company nor any of its subsidiaries is in violation of its
charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<U>Default</U>&#148;) under any
indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing,
securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not
be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and the issuance and sale of the
Shares will not contravene (i)&nbsp;the provisions of the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii)&nbsp;any agreement or other
instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, and (iii)&nbsp;any law, administrative regulation or administrative or court decree applicable to the Company or
any of its subsidiaries; except, in the case of clauses (ii)&nbsp;and (iii), as would not reasonably be expected to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Neither the issue and sale of the Securities nor the consummation of any other of the transactions contemplated by this
Agreement, nor the execution, delivery and performance of this Agreement by the Company, nor the fulfillment of the terms hereof will conflict with, result in a breach or violation of, or imposition of any lien, charge or encumbrance upon any
property or assets of the Company or any of its subsidiaries pursuant to, (i)&nbsp;the charter or bylaws of the Company or any of its subsidiaries, (ii)&nbsp;the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan
agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject, or (iii)&nbsp;any statute, law, rule, regulation, judgment,
order or decree applicable to the Company or any of its subsidiaries of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its subsidiaries or any of its
or their properties, except in the case of clauses (ii)&nbsp;and (iii) for any such breach, violation or imposition as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change and as would not
materially adversely affect the ability of the Underwriters to consummate the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) The historical financial statements of the Company included in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus Supplement present fairly in all material respects the financial condition, results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form in all material respects with
the applicable accounting requirements of the Securities Act and have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Each of the Company and each of its subsidiaries owns or leases all such
properties as are necessary to the conduct of its operations as presently conducted, except as would not reasonably be expected to have a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now
pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with
the employees of the Company exists, except as described in the Final Prospectus Supplement, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of
any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The
Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus Supplement as being owned or licensed by them or which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted
(collectively, &#147;<U>Intellectual Property</U>&#148;) and, to the Company&#146;s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others. The
Intellectual Property owned by the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such
adjudication. To the Company&#146;s knowledge: (i)&nbsp;except as otherwise disclosed in the Final Prospectus Supplement and with respect to LX9211 (to which the Company owns an exclusive license), there are no third parties who have ownership,
royalty, or exclusive license rights to any Intellectual Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus Supplement as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no material infringement by third parties of any Intellectual Property owned by the Company. There
is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property licensed to the Company; (B)&nbsp;challenging the validity,
enforceability or scope of any Intellectual Property owned by the Company; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in
the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other intellectual rights of
others. The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
licensed to the Company or any subsidiary, and all such agreements are, to the Company&#146;s knowledge, in full force and effect. To the Company&#146;s knowledge, there are no material defects
in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company, including the execution
of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term
of any such agreement. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property owned by the
Company have been materially complied with; and in all foreign offices having similar requirements, all such requirements have been materially complied with. The product candidates described in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus Supplement as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) The Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state,
federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement
(&#147;<U>Permits</U>&#148;), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) To the Company&#146;s knowledge, the manufacturing facilities and operations of its suppliers or its subsidiaries are
operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the of the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;) and comparable drug regulatory agencies outside of the United
States to which it is subject (collectively, the &#147;<U>Regulatory Authorities</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) The application of the
proceeds received by the Company from the issuance, sale and delivery of the Securities as described in the Pricing Disclosure Package and the Final Prospectus Supplement will not violate Regulation T, U or X of the Board of Governors of the Federal
Reserve system or any other regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) No consent, approval, authorization, filing with
or order of any court or governmental agency or body is required in connection with the transactions contemplated herein, except such as have been obtained under the Securities Act and such as may be required under the listing rules of the Nasdaq,
applicable rules of the Financial Industry Regulatory Authority, Inc. (&#147;<U>FINRA</U>&#148;) and the blue sky laws of any jurisdiction in connection with the purchase and distribution of the Securities by the Underwriters in the manner
contemplated herein and in the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) Except as otherwise disclosed in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus Supplement, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets owned by them which is material to the business of the Company,
in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects except as do not materially affect the value of such property and do not interfere in any material respect with the use
made and currently proposed to be made of such property by the Company. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with
such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the
Company and its subsidiaries (i)&nbsp;have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii)&nbsp;have paid all taxes required to be paid by any of them and, if due
and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in accordance with generally
accepted accounting principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) There are no transfer taxes or other similar fees or charges under federal law or the
laws of any state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement, any other document to be furnished hereunder or the issuance by the Company or sale by the Company of the
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The Company is not, and will not be, either after receipt of payment for the Shares or after the
application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, required to register as an &#147;investment company&#148; under
the Investment Company Act of 1940, as amended (the &#147;<U>Investment Company Act</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company and each
of its subsidiaries is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company and its subsidiaries are in
compliance with the terms of such policies and instruments in all material respects; and there are no material claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance company is denying
liability or defending under a reservation of rights clause; neither the Company nor any such subsidiary has been refused any insurance coverage sought or applied for; and neither the Company nor any such subsidiary has any reason to believe that it
will not be able to renew its existing insurance coverage as and when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) Except as otherwise disclosed in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus Supplement, no subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s
capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s property or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that
reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Stock or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;<U>Regulation
M</U>&#148;)) with respect to the Common Stock, whether to facilitate the sale or resale of the Shares or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)
There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement which have not been described as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) All of the information provided to the Underwriters or to
counsel for the Underwriters by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true,
complete and correct. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) Neither the Company nor any of its subsidiaries nor, to the best of the Company&#146;s
knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be
disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) Except
as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement and except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i)&nbsp;neither the
Company nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law (including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative
interpretation thereof, relating to pollution or protection of human health (to the extent relating to exposure to Hazardous Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land
surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release of pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any governmental authority (collectively, &#147;<U>Hazardous Materials</U>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials (collectively, &#147;<U>Environmental Laws</U>&#148;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of them under Environmental Laws for their operations has currently conducted
and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii)&nbsp;the Company and its subsidiaries has not received written notice of any pending or threatened liability under any Environmental
Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) Except as would not, individually or in the aggregate, result in a Material Adverse Change: (i)&nbsp;the Company and its
subsidiaries and any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<U>ERISA</U>&#148;))
established or maintained by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA; &#147;<U>ERISA Affiliate</U>&#148; means, with respect to the Company or any
of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
&#147;<U>Code</U>&#148;) of which the Company or such subsidiary is a member; (ii)&nbsp;no &#147;reportable event&#148; (as defined under ERISA), other than an event for which the <FONT STYLE="white-space:nowrap">30-day</FONT> notice period is
waived, has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates; (iii)&nbsp;no &#147;employee benefit
plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under
ERISA); (iv) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee
benefit plan&#148; or (b)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code; and (v)&nbsp;each &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be
qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) The Company and its subsidiaries are in compliance with all applicable laws, rules and regulations, except where failure
to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) Neither the Company nor any of its subsidiaries nor, to the knowledge
of the Company, any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of
its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made or taken any act
in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international
organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<U>FCPA</U>&#148;), the UK
Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) The
operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the &#147;<U>Money Laundering Laws</U>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering
Laws is pending or, to the best knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) The preclinical tests and clinical trials, and
other studies (collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement were and, if still pending, are, to
the Company&#146;s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product
candidates comparable to those being developed by the Company; the descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and
the Company and its subsidiaries have no knowledge of any other studies the results of which reasonably call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any
other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#147;<U>Regulatory Agencies</U>&#148;) except where failure to do so would not result in a Material
Adverse Change; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or
referred to in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) The Company: (A)&nbsp;is in compliance with the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. &#167; 301 et seq.) and the regulations promulgated thereunder (the &#147;<U>FDCA</U>&#148;) except where failure to be so in compliance would not result in a Material Adverse Change; (B)&nbsp;has not received any FDA Form
483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA alleging or asserting material noncompliance with the FDCA or any licenses, certificates, approvals, clearances,
exemptions, authorizations, permits and supplements or amendments thereto required under the FDCA (&#147;<U>Authorizations</U>&#148;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the
Company is not in material violation of any term of any such Authorizations except where failure to possess or be so in compliance with such Authorizations would not reasonably be expected to result in a Material Adverse Change; (D)&nbsp;has not
received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material
violation of the FDCA or the terms of any Authorization and has no knowledge that the FDA or any governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, which if resolved
adversely to the Company, would reasonably be expected to have a Material Adverse Change; (E)&nbsp;has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or
revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required under the FDCA or any Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially
complete and correct on the date filed (or were corrected or supplemented by a subsequent submission), except where instances of failure to file, obtain, maintain or submit required documentation would not reasonably be expected to result in a
Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company,
directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<U>OFAC</U>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury of the United Kingdom, or other
relevant sanctions authority (collectively, &#147;<U>Sanctions</U>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without
limitation, the Crimea region and the Donetsk People&#146;s Republic and Luhansk People&#146;s Republic in Ukraine, Cuba, Iran, North Korea, Syria, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic and Luhansk People&#146;s Republic regions of Ukraine (collectively, the &#147;<U>Sanctioned
Countries</U>&#148;); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the
purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person
(including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly
engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) The Company and the Company&#146;s directors or officers, in their capacities as such, are in compliance, in all material
respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) The Company&#146;s and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks,
hardware, and databases (collectively, &#147;<U>IT Systems</U>&#148;) are reasonably adequate for the operation of the business of the Company and its subsidiaries as currently conducted. The Company and its subsidiaries have implemented and
maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, operation, redundancy and security of all IT
Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<U>Personal Data</U>&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number,
<FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, or bank account information; (ii)&nbsp;any information which
would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR (as defined below); (iv) any information which would qualify as &#147;protected
health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<U>HIPAA</U>&#148;); and (v)&nbsp;any other
piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation, and together with all
proprietary or confidential information of the Company, &#147;<U>Sensitive Data</U>&#148;. In the past three (3)&nbsp;years, there have been no breaches, violations, outages or unauthorized uses of or accesses to such Sensitive Data or IT Systems,
except for those that have been remedied without material cost or liability or the duty to notify any other person under Privacy Laws (as defined below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and
federal data privacy and security laws and regulations, including without limitation HIPAA, the European Union General Data Protection Regulation (&#147;<U>EU GDPR</U>&#148;) (EU 2016/679) and the United Kingdom General Data Protection Regulation (
&#147;UK GDPR&#148;), and all state privacy laws (including the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
California Consumer Privacy Act (&#147;CCPA&#148;) and similar laws in any other states) (collectively, the &#147;<U>Privacy Laws</U>&#148;). To ensure compliance with the Privacy Laws, the
Company and its subsidiaries have in place, comply with, and take appropriate steps to ensure compliance in all material respects with the Company&#146;s policies and procedures relating to data privacy and security and the collection, storage, use,
disclosure, handling, and analysis of Sensitive Data (the &#147;<U>Policies</U>&#148;). The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received written notice of any actual or potential liability under or relating to,
or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any
Privacy Law; or (iii)&nbsp;is a party to any order, decree, or settlement agreement issued by a governmental authority that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) The Company (i)&nbsp;does not have any material lending or other relationship with any bank or lending affiliate of the
Underwriters and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate of the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) The Company and its subsidiaries are, and at all times have been, in compliance with all applicable Health Care Laws,
except to the extent that any <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. For purposes of this Agreement, &#147;<U>Health Care
Laws</U>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable
federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C.
Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C.
Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare
programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and
Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational
and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart
thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or
other action threatened, except in each case as would not, individually or in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
aggregate, reasonably be expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and
accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees,
officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation,
proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) The statements contained in the Preliminary Prospectus Supplement and the Final Prospectus Supplement under the captions
&#147;Business&#151;Patents and Proprietary Rights,&#148; &#147;Business&#151;Government Regulation,&#148; &#147;Risk Factors&#151;Risks Related to Our Intellectual Property,&#148; insofar as such statements summarize legal matters, agreements,
documents, or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements, documents or proceedings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) Any certificate signed by any officer of the Company and delivered to the Underwriters or counsel for the Underwriters in
connection with the offering of the Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Underwriters, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee) No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) contained in either the Pricing Disclosure Package or the Final Prospectus Supplement has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(fff) Neither the Company nor any of its affiliates (within the meaning of FINRA Rule 5121(f)(1)) directly or indirectly
controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article I, Section&nbsp;1(ee) of the bylaws of FINRA) of, any member firm of FINRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Company
agrees to sell to each Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company, at the purchase price set forth in <U>Schedule I</U> hereto, the number of Underwritten Securities set forth opposite such
Underwriter&#146;s name in <U>Schedule</U><U></U><U>&nbsp;II</U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and conditions and in reliance upon the
representations and warranties herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to the number of Option Securities set forth in <U>Schedule I</U> hereto at the same purchase
price per share as the Underwriters shall pay for the Underwritten Securities, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Securities but not payable on the Option
Securities. Said option may be exercised in whole or in part at any time on or before the 30th day after the date of the Final Prospectus Supplement upon written or telegraphic notice by the Representatives to the Company setting forth the number of
Option Securities as to which the several Underwriters are exercising the option and the settlement date. The number of Option Securities to be purchased by each Underwriter shall be the same percentage of the total number of Option Securities to be
purchased by the several Underwriters as such Underwriter is purchasing of the Underwritten Securities, subject to such adjustments as you in your absolute discretion shall make to eliminate any fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Delivery and Payment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Delivery of and payment for the Underwritten Securities and the Option Securities (if the option provided for in
Section&nbsp;2(b) hereof shall have been exercised on or before the first Business Day immediately preceding the Closing Date) shall be made on the date and at the time specified in <U>Schedule I</U> hereto or at such time on such later date not
more than two Business Days after the foregoing date as the Representatives shall designate, which date and time may be postponed by agreement between the Representatives and the Company or as provided in Section&nbsp;9 hereof (such date and time of
delivery and payment for the Securities being herein called the &#147;<U>Closing Date</U>&#148;). As used herein, &#147;Business Day&#148; shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions
or trust companies are authorized or obligated by law to close in New York City. Delivery of the Securities shall be made to the Representatives for the respective accounts of the several Underwriters against payment by the several Underwriters
through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer payable in <FONT STYLE="white-space:nowrap">same-day</FONT> funds to an account specified by the Company. Delivery of the Underwritten
Securities (other than the Warrants) and the Option Securities shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the option provided for in Section&nbsp;2(b) hereof is exercised after the third Business Day immediately preceding the
Closing Date, the Company will deliver the Option Securities (at the expense of the Company) to the Representatives, at 388 Greenwich Street, New York, New York, on the date specified by the Representatives (which shall be within three Business Days
after exercise of said option) for the respective accounts of the several Underwriters, against payment by the several Underwriters through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer
payable in <FONT STYLE="white-space:nowrap">same-day</FONT> funds to an account specified by the Company. If settlement for the Option Securities occurs after the Closing Date, the Company will deliver to the Representatives on the settlement date
for the Option Securities, and the obligation of the Underwriters to purchase the Option Securities shall be conditioned upon receipt of, supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and
letters delivered on the Closing Date pursuant to Section&nbsp;6 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Offering by Underwriters</U>. It is understood that the several Underwriters propose
to offer the Securities for sale to the public as set forth in the Final Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Agreements</U>. The Company agrees
with the several Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the termination of the offering of the Securities, the Company will not
file any amendment of the Registration Statement or supplement (including the Final Prospectus Supplement or any Preliminary Prospectus Supplement) to the Base Prospectus or any Rule&nbsp;462(b) Registration Statement unless the Company has
furnished you a copy for your review prior to filing and will not file any such proposed amendment or supplement to which you reasonably object. The Company will cause the Final Prospectus Supplement, properly completed, and any supplement thereto
to be filed in a form approved by the Representatives with the SEC pursuant to the applicable paragraph of Rule&nbsp;424(b) within the time period prescribed and will provide evidence satisfactory to the Representatives of such timely filing. The
Company will promptly advise the Representatives (i)&nbsp;when the Final Prospectus Supplement, and any supplement thereto, shall have been filed (if required) with the SEC pursuant to Rule&nbsp;424(b) or when any Rule&nbsp;462(b) Registration
Statement shall have been filed with the SEC, (ii)&nbsp;when, prior to termination of the offering of the Securities, any amendment to the Registration Statement shall have been filed or become effective, (iii)&nbsp;of any request by the SEC or its
staff for any amendment of the Registration Statement, or any Rule&nbsp;462(b) Registration Statement, or for any supplement to the Final Prospectus Supplement or for any additional information, (iv)&nbsp;of the issuance by the SEC of any stop order
suspending the effectiveness of the Registration Statement or of any notice objecting to its use or the institution or threatening of any proceeding for that purpose and (v)&nbsp;of the receipt by the Company of any notification with respect to the
suspension of the qualification of the Securities for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its best efforts to prevent the issuance of any such stop order or the
occurrence of any such suspension or objection to the use of the Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief from such occurrence or
objection, including, if necessary, by filing an amendment to the Registration Statement or a new registration statement and using its best efforts to have such amendment or new registration statement declared effective as soon as practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, at any time prior to the filing of the Final Prospectus Supplement pursuant to Rule 424(b), any event occurs as a
result of which the Pricing Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or
the circumstances then prevailing not misleading, the Company will (i)&nbsp;notify promptly the Representatives so that any use of the Pricing Disclosure Package may cease until it is amended or supplemented; (ii)&nbsp;amend or supplement the
Pricing Disclosure Package to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to you in such quantities as you may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, at any time when a prospectus relating to the Securities is required
to be delivered under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172), any event occurs as a result of which the Final Prospectus Supplement as then supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, or if it shall be
necessary to amend the Registration Statement, file a new registration statement or supplement the Final Prospectus Supplement to comply with the Securities Act or the Exchange Act or the respective rules thereunder, including in connection with use
or delivery of the Final Prospectus Supplement, the Company promptly will (i)&nbsp;notify the Representatives of any such event, (ii)&nbsp;prepare and file with the SEC, subject to the second sentence of paragraph (a)&nbsp;of this Section&nbsp;5, an
amendment or supplement or new registration statement which will correct such statement or omission or effect such compliance, (iii)&nbsp;use its best efforts to have any amendment to the Registration Statement or new registration statement declared
effective as soon as practicable in order to avoid any disruption in use of the Final Prospectus Supplement and (iv)&nbsp;supply any supplemented Final Prospectus Supplement to you in such quantities as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) As soon as practicable, the Company will make generally available to its security holders and to the Representatives an
earnings statement or statements of the Company and its subsidiaries which will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company will furnish to the Representatives and counsel for the Underwriters, without charge, signed copies of the
Registration Statement (including exhibits thereto) and to each other Underwriter a copy of the Registration Statement (without exhibits thereto) and, so long as delivery of a prospectus by an Underwriter or dealer may be required by the Securities
Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172), as many copies of each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each Issuer Free Writing Prospectus and any supplement
thereto as the Representatives may reasonably request. The Company will pay the expenses of printing or other production of all documents relating to the offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company will arrange, if necessary, for the qualification of the Securities for sale under the laws of such
jurisdictions as the Representatives may designate and will maintain such qualifications in effect so long as required for the distribution of the Securities; <I>provided</I> that in no event shall the Company be obligated to qualify to do business
in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Securities, in any jurisdiction where it is not now so
subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company will not, without the prior written consent of the Citigroup
Global Markets Inc., offer, sell, contract to sell, pledge, hedge, or otherwise dispose of, (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or
effective economic disposition due to cash settlement or otherwise) by the Company&nbsp;or any affiliate of the Company or any person in privity with the Company or any affiliate of the Company) directly or indirectly, including the submission or
filing (or participation in the submission or filing) of a registration statement with the SEC in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of
Section&nbsp;16 of the Exchange Act, any other shares of Common Stock or any securities convertible into, or exercisable, or exchangeable for, shares of Common Stock; or publicly announce an intention to effect any such transaction, for a period of
60 days after the date of this Agreement (such period, the &#147;<U>Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</U>&#148;), <I>provided</I>, <I>however</I>, that the Company may: (i)&nbsp;effect the transactions contemplated
hereby and issue shares of Common Stock pursuant to the potential concurrent private placement described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement; (ii)&nbsp;issue warrants to purchase shares
of Common Stock with a value equal to $437,500, as required in the event that the Company elects to obtain a Term B Loan within 30 days upon the FDA&#146;s acceptance of the Company&#146;s NDA for sotagliflozin pursuant to the Company&#146;s Loan
and Security Agreement, dated March&nbsp;17, 2022, with Oxford Finance, LLC, provided that if any filing under Section&nbsp;16(a) of the Exchange Act shall be legally required during the Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (iii)&nbsp;grant options, restricted stock units or other equity awards or issue shares of Common Stock to its
employees, officers, directors, advisors or consultants pursuant to employee benefit plans of the Company, <I>provided</I>, that each recipient of such securities that is a newly appointed director or executive officer pursuant to this clause
(iii)&nbsp;agree to restrictions on the resale of securities that are consistent with the provisions set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;6(l) hereof; and (iv)&nbsp;file one or more
registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to stock options or employee benefit plans of the Company, and <I>provided</I>, <I>further</I>, that each recipient of such securities that is a newly appointed
director or executive officer agrees to restrictions on the resale of securities that are consistent with the provisions set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> letter described in Section&nbsp;6(l) hereof. The Company will
provide the Representatives and each individual subject to the restricted period pursuant to the <FONT STYLE="white-space:nowrap">lock-up</FONT> letters described in Section&nbsp;6(l) hereof with prior notice of any such announcement that gives rise
to an extension of the restricted period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company will use its reasonable best efforts to maintain the listing of
the Shares issued and sold by the Company on The Nasdaq Global Select Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company will not take, directly or
indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the
sale or resale of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company agrees to pay the costs and expenses relating to the
following matters: (i)&nbsp;the preparation, printing or reproduction and filing with the SEC of the Registration Statement (including financial statements and exhibits thereto), each Preliminary Prospectus Supplement, the Final Prospectus
Supplement and each Issuer Free Writing Prospectus, and each amendment or supplement to any of them; (ii)&nbsp;the printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies
of the Registration Statement, each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each Issuer Free Writing Prospectus, and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use
in connection with the offering and sale of the Securities; (iii)&nbsp;the preparation, printing, authentication, issuance and delivery of certificates for the Securities, including any stamp or transfer taxes in connection with the original
issuance and sale of the Securities; (iv)&nbsp;the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with the offering of the
Securities; (v)&nbsp;the registration of the Securities under the Exchange Act and the listing of the Securities on Nasdaq; (vi)&nbsp;any registration or qualification of the Securities for offer and sale under the securities or blue sky laws of the
several states (including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such registration and qualification); (vii)&nbsp;FINRA (including filing fees and the reasonable fees and expenses of counsel for
the Underwriters relating to such filings); (viii)&nbsp;the transportation and other expenses incurred by or on behalf of Company representatives in connection with presentations to prospective purchasers of the Securities; (ix)&nbsp;the fees and
expenses of the Company&#146;s accountants and the fees and expenses of counsel (including local and special counsel) for the Company; and (x)&nbsp;all other costs and expenses incident to the performance by the Company of its obligations hereunder,
<I>provided</I>, <I>however</I>, that the reasonable fees and expenses of counsel for the Underwriters incurred pursuant to clauses (vi)&nbsp;and (vii) of this Section&nbsp;5(j) shall not exceed $20,000 in the aggregate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company agrees that, unless it has or shall have obtained the prior written consent of the Representatives, and each
Underwriter, severally and not jointly, agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, it has not made and will not make any offer relating to the Securities that
would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company with the SEC or retained by the Company under Rule 433 under the Securities Act (&#147;<U>Rule
433</U>&#148;); <I>provided</I> that the prior written consent of the parties hereto shall be deemed to have been given in respect of the Free Writing Prospectuses included in <U>Schedule III</U> hereto and any electronic road show. The Company
agrees that (x)&nbsp;it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (y)&nbsp;it has complied and will comply, as the case may be, with the requirements of Rule 164
under the Securities Act (&#147;<U>Rule 164</U>&#148;) and Rule 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the SEC, legending and record keeping. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions to the Obligations of the Underwriters</U>. The obligations of the
Underwriters to purchase the Underwritten Securities and the Option Securities, as the case may be, shall be subject to the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, the
Closing Date and any settlement date pursuant to Section&nbsp;3 hereof, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and
to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Final Prospectus Supplement, and any supplement thereto, have been filed
in the manner and within the time period required by Rule&nbsp;424(b); any material required to be filed by the Company pursuant to Rule 433(d) shall have been filed with the SEC within the applicable time periods prescribed for such filings by Rule
433; and no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use shall have been issued and no proceedings for that purpose shall have been instituted or threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall have requested and caused Brian T. Crum, Senior Vice President and General Counsel of the Company, to
have furnished to the Representatives an opinion, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall have requested and caused Max Bachrach, Ph.D., Vice President, Intellectual Property, of the Company, to
have furnished to the Representatives an opinion with respect to intellectual property matters, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company shall have requested and caused Vinson&nbsp;&amp; Elkins LLP, counsel for the Company, to have furnished to the
Representatives their opinion and negative assurance letter, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Representatives shall have received from Cooley LLP, counsel for the Underwriters, such opinion or opinions and
negative assurance letter, dated the Closing Date and addressed to the Representatives, with respect to the issuance and sale of the Securities, the Registration Statement, the Pricing Disclosure Package, the Final Prospectus Supplement (together
with any supplement thereto) and other related matters as the Representatives may reasonably require, and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company shall have furnished to the Representatives a certificate of the Company, signed by the Chief Executive
Officer or other principal executive officer of the Company, dated the Closing Date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the Pricing Disclosure Package, the Final Prospectus
Supplement and any amendments or supplements thereto, as well as each electronic road show used in connection with the offering of the Securities, and this Agreement and that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the representations and warranties of the Company in this Agreement are true and correct on and as of the Closing Date with
the same effect as if made on the Closing Date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) no stop order suspending the effectiveness of the Registration
Statement or any notice objecting to its use has been issued and no proceedings for that purpose have been instituted or, to the Company&#146;s knowledge, threatened; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) since the date of the most recent financial statements included or incorporated by reference in the Pricing Disclosure
Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto), there has been no Material Adverse Change in the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its
subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or
supplement thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company shall have requested and caused Ernst&nbsp;&amp; Young LLP to have furnished to the
Representatives, at the Execution Time and at the Closing Date, letters (which may refer to letters previously delivered to one or more of the Representatives), dated respectively as of the Execution Time and as of the Closing Date, in form and
substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountants &#147;comfort letters&#148; to underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Subsequent to the Execution Time or, if earlier, the dates as of which information is given in the Registration Statement
(exclusive of any amendment thereof) and the Final Prospectus Supplement (exclusive of any supplement thereto), there shall not have been (i)&nbsp;any change or decrease specified in the letter or letters referred to in paragraph&nbsp;(e) of this
Section&nbsp;6 or (ii)&nbsp;any change, or any development involving a prospective change, in or affecting the condition (financial or otherwise), earnings, business or properties of the Company and its subsidiaries taken as a whole, whether or not
arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto) the effect of which, in any
case referred to in clause&nbsp;(i) or (ii)&nbsp;above, is, in the sole judgment of the Representatives, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by
the Registration Statement (exclusive of any amendment thereof), the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Prior to the Closing Date, the Company shall have furnished to the
Representatives such further information, certificates and documents as the Representatives may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)
Subsequent to the Execution Time, there shall not have been any decrease in the rating of any of the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization&#148; (as defined for purposes of Rule 3(a)(62)
under the Exchange Act) or any notice given of any intended or potential decrease in any such rating or of a possible change in any such rating that does not indicate the direction of the possible change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Securities shall have been listed and admitted and authorized for trading on Nasdaq, and satisfactory evidence of such
actions shall have been provided to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) At the Execution Time, the Company shall have furnished to
the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter substantially in the form of <U>Exhibit A</U> hereto from each executive officer and director of the Company and certain stockholders of the Company addressed to the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the conditions specified in this Section&nbsp;6 shall not have been fulfilled when and as provided in this
Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters, this Agreement and all
obligations of the Underwriters hereunder may be canceled at, or at any time prior to, the Closing Date by the Representatives. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed in writing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents required to be delivered by this Section&nbsp;6 shall be delivered electronically to Cooley LLP, counsel for the
Underwriters, on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Reimbursement of Underwriters&#146; Expenses</U>. If the sale of the Securities provided for
herein is not consummated because any condition to the obligations of the Underwriters set forth in Section&nbsp;6 hereof is not satisfied, because of any termination pursuant to Section&nbsp;10 hereof or because of any refusal, inability or failure
on the part of the Company to perform any agreement herein or comply with any provision hereof other than by reason of a default by any of the Underwriters, the Company will reimburse the Underwriters severally through Citigroup Global Markets Inc.
on demand for all expenses (including reasonable fees and disbursements of counsel) that shall have been incurred by them in connection with the proposed purchase and sale of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Underwriter, the directors, officers, employees, affiliates and
agents of each Underwriter and each person who controls any Underwriter within the meaning of either the Securities Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them
may become subject under the Securities Act, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of
or are based upon any untrue statement or alleged untrue statement of a material fact contained in the registration statement for the registration of the Securities as originally filed or in any amendment thereof, or in the Base Prospectus, any
Preliminary Prospectus Supplement or any other preliminary prospectus supplement relating to the Securities, the Final Prospectus Supplement, or any Issuer Free Writing Prospectus or in any amendment thereof or supplement thereto, or arise out of or
are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and agrees to reimburse each such indemnified party, as incurred, for any
legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; <I>provided</I>, <I>however</I>, that the Company will not be liable in any such case to the extent
that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to
the Company by or on behalf of any Underwriter through the Representatives specifically for inclusion therein. This indemnity agreement will be in addition to any liability which the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, each
of its officers who signs the Registration Statement, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, to the same extent as the foregoing indemnity from the Company to each Underwriter,
but only with reference to written information relating to such Underwriter furnished to the Company by or on behalf of such Underwriter through the Representatives specifically for inclusion in the documents referred to in the foregoing indemnity.
This indemnity agreement will be in addition to any liability which any Underwriter may otherwise have. The Company acknowledges that the statements set forth (i)&nbsp;in the last paragraph of the cover page regarding delivery of the Securities and,
under the heading &#147;Underwriting&#148; (ii)&nbsp;the list of Underwriters and their respective participation in the sale of the Securities, (iii)&nbsp;the sentences related to concessions and reallowances and (iv)&nbsp;the paragraph related to
stabilization, syndicate covering transactions and penalty bids in any Preliminary Prospectus Supplement and the Final Prospectus Supplement constitute the only information furnished in writing by or on behalf of the several Underwriters for
inclusion in any Preliminary Prospectus Supplement, the Final Prospectus Supplement or any Issuer Free Writing Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this Section&nbsp;8 of notice of the commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;8, notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party
(i)&nbsp;will not relieve it from liability under paragraph&nbsp;(a) or&nbsp;(b) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the indemnifying party of substantial rights and
defenses and (ii)&nbsp;will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in paragraph&nbsp;(a) or (b)&nbsp;above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party&#146;s choice at the indemnifying party&#146;s expense to represent
the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except
as set forth below); <I>provided</I>, <I>however</I>, that such counsel shall be satisfactory to the indemnified party. Notwithstanding the indemnifying party&#146;s election to appoint counsel to represent the indemnified party in an action, the
indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i)&nbsp;the use of counsel chosen by the
indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii)&nbsp;the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying
party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, (iii)&nbsp;the
indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action or (iv)&nbsp;the indemnifying party shall authorize
the indemnified party to employ separate counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment
with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action)
unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such claim, action, suit or proceeding and (ii)&nbsp;does not include a statement as to or an
admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the event that the
indemnity provided in paragraph&nbsp;(a), (b) or (c)&nbsp;of this Section&nbsp;8 is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company and the Underwriters severally agree to contribute to the aggregate
losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending the same) (collectively, &#147;<U>Losses</U>&#148;) to which the Company and one or more of the Underwriters
may be subject in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and by the Underwriters on the other from the offering of the Securities. If the allocation provided by the immediately
preceding sentence is unavailable for any reason, the Company and the Underwriters severally shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand
and of the Underwriters on the other in connection with the statements or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal to the total net
proceeds from the offering (before deducting expenses) received by it, and benefits received by the Underwriters shall be deemed to be equal to the total underwriting discounts and commissions, in each case as set forth on the cover page of the
Final Prospectus Supplement. Relative fault shall be determined by reference to, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
among other things, whether any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information provided by the
Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree
that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this
paragraph (d), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities
exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this paragraph&nbsp;(d), no person
guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;8,
each person who controls an Underwriter within the meaning of either the Securities Act or the Exchange Act and each director, officer, employee, affiliate and agent of an Underwriter shall have the same rights to contribution as such Underwriter,
and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director of the Company shall have the same rights to
contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph&nbsp;(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Default by an
Underwriter</U>. If any one or more Underwriters shall fail to purchase and pay for any of the Securities agreed to be purchased by such Underwriter or Underwriters hereunder and such failure to purchase shall constitute a default in the performance
of its or their obligations under this Agreement, the remaining Underwriters shall be obligated severally to take up and pay for (in the respective proportions which the amount of Securities set forth opposite their names in
<U>Schedule</U><U></U><U>&nbsp;II</U> hereto bears to the aggregate amount of Securities set forth opposite the names of all the remaining Underwriters) the Securities which the defaulting Underwriter or Underwriters agreed but failed to purchase;
<I>provided</I>, <I>however</I>, that in the event that the aggregate amount of Securities which the defaulting Underwriter or Underwriters agreed but failed to purchase shall exceed 10% of the aggregate amount of Securities set forth in
<U>Schedule</U><U></U><U>&nbsp;II</U> hereto, the remaining Underwriters shall have the right to purchase all, but shall not be under any obligation to purchase any, of the Securities, and if such
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not purchase all the Securities, this Agreement will terminate without liability to any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company. In the
event of a default by any Underwriter as set forth in this Section&nbsp;9, the Closing Date shall be postponed for such period, not exceeding five Business Days, as the Representatives shall determine in order that the required changes in the
Registration Statement and the Final Prospectus Supplement or in any other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve any defaulting Underwriter of its liability, if any, to the Company and any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages occasioned by its default hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Termination</U>. This Agreement shall be subject to termination in the absolute
discretion of the Representatives, by notice given to the Company prior to delivery of and payment for the Securities, if at any time prior to such delivery and payment (i)&nbsp;trading in the Company&#146;s Common Stock shall have been suspended by
the SEC or Nasdaq or trading in securities generally on the New York Stock Exchange or Nasdaq shall have been suspended or limited or minimum prices shall have been established on either of such exchanges, (ii)&nbsp;a banking moratorium shall have
been declared either by Federal or New York State authorities, (iii)&nbsp;there shall have occurred a material disruption in commercial banking or securities settlement or clearance services or (iv)&nbsp;there shall have occurred any outbreak or
escalation of hostilities, declaration by the United States of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Representatives, impractical or
inadvisable to proceed with the offering or delivery of the Securities as contemplated by any Preliminary Prospectus Supplement or the Final Prospectus Supplement (exclusive of any amendment or supplement thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Representations and Indemnities to Survive</U>. The respective agreements, representations, warranties, indemnities and other
statements of the Company or its officers and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of
the officers, directors, employees, agents, affiliates or controlling persons referred to in Section&nbsp;8 hereof, and will survive delivery of and payment for the Securities. The provisions of Sections&nbsp;7 and 8 hereof shall survive the
termination or cancellation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. All communications hereunder will be in writing and effective only on
receipt, and, if sent to the Representatives, will be mailed, delivered, telefaxed to c/o Citigroup Global Markets Inc. at 388 Greenwich Street, New York, New York 10013, Attention: General Counsel, facsimile number: +1 (646) <FONT
STYLE="white-space:nowrap">291-1469</FONT> and Piper Sandler&nbsp;&amp; Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402, attention: General Counsel, LegalCapMarkets@psc.com; or, if sent to Lexicon Pharmaceuticals, Inc., will be mailed,
delivered or telefaxed to 2445 Technology Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, The Woodlands, Texas 77381, Attention: General Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and
the officers, directors, employees, agents and controlling persons referred to in Section&nbsp;8 hereof, and no other person will have any right or obligation hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Jurisdiction</U>. The Company agrees that any suit, action or proceeding against the Company brought by any Underwriter, the directors,
officers, employees, affiliates and agents of any Underwriter, or by any person who controls any Underwriter, arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in any State or U.S. federal court in
The City of New York and County of New York, and waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction
of such courts in any suit, action or proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Recognition of the U.S. Special Resolution Regimes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;15, &#147;<U>BHC Act Affiliate</U>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); &#147;<U>Covered Entity</U>&#148; means any of the
following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;252.82(b), (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167;&nbsp;47.3(b) or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;&nbsp;382.2(b); &#147;<U>Default Right</U>&#148; has the meaning assigned to that term in, and shall
be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and &#147;<U>U.S. Special Resolution Regime</U>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder
and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.
<U>No Fiduciary Duty</U>. The Company hereby acknowledges that (a)&nbsp;the purchase and sale of the Securities pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on
the one hand, and the Underwriters and any affiliate through which it may be acting, on the other, (b)&nbsp;the Underwriters are acting as principal and not as an agent or fiduciary of the Company and (c)&nbsp;the Company&#146;s engagement of the
Underwriters in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity. Furthermore, the Company agrees that it is solely responsible for making its own judgments in
connection with the offering (irrespective of whether any of the Underwriters has advised or is currently advising the Company on related or other matters). The Company agrees that it will not claim that the Underwriters have rendered advisory
services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Integration</U>. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and
the Underwriters, or any of them, with respect to the subject matter hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Applicable Law</U>. This Agreement will be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and to be performed within the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Waiver of
Jury Trial</U>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Counterparts</U>. This Agreement may be signed in one or more counterparts, each of which shall constitute an original and
all of which together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Headings</U>. The section headings used herein are for convenience only and shall not affect the construction hereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall represent a binding agreement among the Company and the several Underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEXICON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">confirmed and accepted as of the date</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">specified in <U>Schedule I</U> hereto.</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CITIGROUP GLOBAL MARKETS INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PIPER SANDLER&nbsp;&amp; CO.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CITIGROUP GLOBAL MARKETS INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Brock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Brock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PIPER SANDLER&nbsp;&amp; CO.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Neil Riley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Neil Riley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">For themselves and the other
several </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters named in <U>Schedule II</U> to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">the foregoing Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement]</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE&nbsp;I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriting Agreement, dated July&nbsp;27, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registration
Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-258564</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representatives: Citigroup Global Markets Inc. and Piper Sandler&nbsp;&amp; Co.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title, Purchase Price and Description of Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Title: Common Stock, par value $0.001 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Underwritten Securities to be sold by the Company: 16,843,600 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Option Securities to be sold by the Company: 2,526,540 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Price per Share to Public (include accrued dividends, if any): $2.50 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Price per Share to the Underwriters &#150; total: $2.35 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Other provisions: None. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Closing Date, Time and
Location: August&nbsp;1, 2022 at 10:00 a.m., New York City time, at Cooley LLP, 55 Hudson Yards, New York, New York 10001 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Type of Offering: <FONT
STYLE="white-space:nowrap">Non-Delayed</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE&nbsp;II </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Underwritten<BR>Securities&nbsp;to&nbsp;be&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,685,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,158,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,843,600</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE&nbsp;III </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule of Free Writing Prospectuses included in the Pricing Disclosure Package </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">___________________, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global
Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
Representatives of the several Underwriters </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Citigroup Global Markets Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10013 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Piper Sandler&nbsp;&amp; Co. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Minneapolis,
Minnesota 55402 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned
understands that Citigroup Global Markets Inc. (&#147;<U>Citigroup</U>&#148;) and Piper Sandler&nbsp;&amp; Co. (together with Citigroup, the &#147;<U>Representatives</U>&#148;) propose to enter into an Underwriting Agreement (the
&#147;<U>Underwriting Agreement</U>&#148;) with Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), providing for the public offering (the &#147;<U>Offering</U>&#148;) by the several Underwriters listed in
Schedule II to the Underwriting Agreement (the &#147;<U>Underwriters</U>&#148;) of shares (the &#147;<U>Shares</U>&#148;) of the common stock, par value $0.001 per share, of the Company (the &#147;<U>Common Stock</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To induce the Underwriters that may participate in the Offering to continue their efforts in furtherance thereof, the undersigned hereby agrees not to, during
the period commencing on the date hereof and ending 60 days after the date of the final prospectus supplement relating to the Offering (the &#147;<U>Prospectus</U>&#148;) (&#147;such period, the
&#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#148;), without the prior written consent of Citigroup on behalf of the Underwriters, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common
Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1)&nbsp;or (2) above is
to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a)&nbsp;transactions relating to shares of Common Stock or other securities acquired in open market transactions
after the completion of the Offering, <I>provided</I> that no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired in such
open market transactions, (b)&nbsp;any surrender of shares of Common Stock (or options to purchase shares of Common Stock) to the Company by the undersigned in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfaction of (i)&nbsp;any federal, state or local taxes required by law to be withheld with respect to the vesting of shares of Common Stock or the exercise of stock options to purchase Common
Stock and/or (ii)&nbsp;the exercise price payable to the Company with respect to the exercise of stock options to purchase Common Stock, in each case granted under a stock incentive plan or stock purchase plan of the Company described in the
Prospectus or any document incorporated by reference therein and in accordance with the terms of any such instrument as in effect on or before the date hereof, (c)&nbsp;transfers of shares of Common Stock or any security convertible into Common
Stock as a bona fide gift, (d)&nbsp;distributions of shares of Common Stock or any security convertible into Common Stock to limited partners, members, stockholders or equityholders of the undersigned, (e)&nbsp;transfers to immediate family of the
undersigned, to a trust all of the beneficiaries of which are the undersigned and/or members of his or her immediate family or to a corporation, partnership, limited partnership or limited liability company all of the stockholders, partners and
members of which are the undersigned and/or members of his or her immediate family, in each case for estate planning purposes, (f)&nbsp;transfers by will or other testamentary document, or intestacy; <I>provided</I> that (i)&nbsp;in the case of any
transfer or distribution pursuant to clauses (c) &#150; (f) each donee or distributee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of this agreement and (ii)&nbsp;in the case of any
surrender, transfer or distribution pursuant to clauses (b) &#150; (f), no filing under Section&nbsp;16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made
during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, (g)&nbsp;the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock;
<I>provided</I> that such plan does not provide for the transfer of Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, except as otherwise permitted herein, and no public announcement or filing under the Exchange Act
regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period or (h)&nbsp;by operation of law, such as pursuant
to a qualified domestic order, divorce settlement, divorce decree or separation agreement; <I>provided</I> that if any filing under Section&nbsp;16(a) of the Exchange Act shall be legally required during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer. For purposes of this agreement, &#147;immediate family&#148;
shall mean spouse, lineal descendant, father, mother, brother or sister of the transferor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the undersigned agrees that, without the prior
written consent of Citigroup on behalf of the Underwriters, it will not, during the period commencing on the date hereof and ending 60 days after the date of the Prospectus, make any demand for or exercise any right with respect to, the registration
of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar
against the transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this agreement or the subject matter hereof, and the undersigned has
consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect to this agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees
that, although the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with the Offering, the Underwriters are not making a recommendation to you to participate in
the Offering or sell any shares at the price determined in the Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such a recommendation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement may be delivered via facsimile, electronic mail (including pdf or any
electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall automatically terminate, and the undersigned shall be automatically released
from its obligations hereunder, upon the earliest to occur, if any, of (1)&nbsp;the execution of the Underwriting Agreement in connection with the Offering shall not have occurred on or before August&nbsp;31, 2022, (2) the Underwriting Agreement
(other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder or (3)&nbsp;the Representatives, on behalf of the Underwriters, advise the
Company, or the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this agreement. This
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Securityholder (Print exact name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory (Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory (Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d342123dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g342123g0729025542233.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;28, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Technology Forest Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Woodlands, TX 77381 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), with
respect to certain legal matters in connection with the proposed issuance and sale by the Company of 19,370,140 shares (the &#147;<U>Shares</U>&#148;) of common stock, par value $0.001 (the &#147;<U>Common Stock</U>&#148;). The Shares are being
offered, issued and sold pursuant to an Underwriting Agreement dated July&nbsp;27, 2022 by and among the Company, and Citigroup Global Markets Inc. and Piper Sandler&nbsp;&amp; Co., as representatives for the several underwriters named in Schedule
II thereto (the &#147;<U>Underwriting Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have participated in the preparation of a Prospectus
Supplement dated July&nbsp;27, 2022 (the &#147;<U>Prospectus Supplement</U>&#148;), forming part of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> effective as of September&nbsp;14, 2021 (the &#147;<U>Registration
Statement</U>&#148;), that also contains a base prospectus (the &#147;<U>Base Prospectus</U>&#148; and, together with the Prospectus Supplement, the &#147;<U>Prospectus</U>&#148;). The Prospectus Supplement has been filed pursuant to Rule 424(b)
promulgated under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In rendering the opinions set forth below, we have examined and relied upon (i)&nbsp;the Registration Statement and the
Prospectus; (ii)&nbsp;the Fifth Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof; (iii)&nbsp;the Second Amended and Restated Bylaws of the Company, as amended to the date hereof; (iv)&nbsp;the
Underwriting Agreement; (v)&nbsp;resolutions of the Board of Directors of the Company dated July&nbsp;22, 2022 and resolutions of the Pricing Committee of the Board of Directors of the Company dated July&nbsp;27, 2022; and (vi)&nbsp;such other
certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the
Prospectus and the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based upon the foregoing and subject to the assumptions, exceptions,
limitations and qualifications set forth below, we are of the opinion that the Shares, when issued and delivered against payment therefor in accordance with the Underwriting Agreement, will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> except as described in the Registration Statement and the Prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vinson &amp; Elkins LLP Attorneys at Law</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin Dallas Dubai Houston London Los Angeles New York</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richmond
Riyadh San Francisco Tokyo Washington</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">845 Texas Avenue, Suite 4700</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, TX
77002</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Tel </B>+1.713.758.2222 <B>Fax </B>+1.713.758.2346 velaw.com</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g342123g0729025542389.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July 28, 2022 Page 2</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions expressed herein are qualified in the following respects: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. We have assumed that (i)&nbsp;each document submitted to us for review is accurate and complete, each such document that is
an original is authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii)&nbsp;each certificate from governmental officials reviewed by us is accurate, complete and
authentic, and all official public records are accurate and complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. This opinion is limited in all respects to the
federal laws of the United States, the Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of
the laws of any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Company&#146;s
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated on or about the date hereof, to the incorporation by reference of this opinion into the Registration Statement and to the reference to our firm under the caption &#147;Legal
Matters&#148; in the Prospectus forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules
and regulations of the Securities and Exchange Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ Vinson&nbsp;&amp; Elkins L.L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Vinson&nbsp;&amp; Elkins L.L.P.</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d342123dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PURCHASE
AGREEMENT </U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;27, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Artal International
S.C.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">44 rue de la Vall&eacute;e </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">L-2661</FONT> Luxembourg </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luxembourg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Anne Goffard </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Invus Group, L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">750 Lexington Avenue (30th Floor) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: David van Zandt </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2445 Technology Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn:&nbsp;President and Chief
Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (a)&nbsp;that certain Underwriting Agreement being entered into by Lexicon Pharmaceuticals, Inc. (the
&#147;<U>Company</U>&#148;) with the representatives of the underwriters named in Schedule II thereto (the &#147;<U>Underwriters</U>&#148;) concurrently with this Agreement (the &#147;<U>Underwriting Agreement</U>&#148;) providing for the issuance
by the Company to the Underwriters (the &#147;<U>Public Offering</U>&#148;) of 16,843,600 shares (the &#147;<U>Firm Shares</U>&#148;) of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;), plus up to
2,526,540 additional shares of Common Stock (the &#147;<U>Option Shares</U>&#148;) that may be issued pursuant to the Underwriters&#146; option to purchase additional shares of Common Stock provided for in Section&nbsp;2(b) of the Underwriting
Agreement (the &#147;<U>Option</U>&#148;), for sale in a public offering at a price to the public of $2.50 per share (the &#147;<U>Purchase Price</U>&#148;), (b) the Fifth Amended and Restated Certificate of Incorporation of the Company, dated
May&nbsp;20, 2022 (the &#147;<U>Certificate of Incorporation</U>&#148;) and (c)&nbsp;the Registration Rights Agreement, dated as of June&nbsp;17, 2007 (as amended, supplemented or otherwise modified, the &#147;<U>Registration Rights
Agreement</U>&#148;), by and between Invus, L.P. and the Company. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants and agreements herein contained, and intending to be legally bound hereby, pursuant to
Section&nbsp;12.01(c) of the Certificate of Incorporation and Section&nbsp;2.02(a) of the Registration Rights Agreement, each of Artal International S.C.A. (the &#147;<U>Investor</U>&#148;), Artal Group S.A., Artal International Management S.A.,
Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Mr.&nbsp;Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. (the &#147;<U>Invus Entities</U>&#148;), as applicable, hereby waives its rights under
(A)&nbsp;Section&nbsp;12.01 of the Certificate of Incorporation to purchase the Firm Shares and Option Shares in connection with the Public Offering and (B)&nbsp;Section&nbsp;2.02 of the Registration Rights Agreement the opportunity to include in
the Public Offering its Registrable Securities (as defined in the Registration Rights Agreement), and the Investor shall purchase, subject to the terms and conditions herein, (i) 16,173,800 shares of Common Stock (the &#147;<U>Firm Investor
Shares</U>&#148;) and (ii)&nbsp;in the event that the Underwriters exercise the Option, up to 2,426,070 shares of Common Stock (the &#147;<U>Option Investor Shares</U>&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>The Firm Investor Shares</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of the conditions described in Section V, the Investor hereby agrees to purchase the Firm Investor
Shares from the Company at the Purchase Price. The total purchase price for the Firm Investor Shares shall be equal to $40,434,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
closing of the sale of the Firm Investor Shares shall take place concurrently with the closing of the sale of the Firm Shares under the Underwriting Agreement (the &#147;<U>Firm Closing Date</U>&#148;), (i) with payment for the Firm Investor Shares
to be made to the Company by wire transfer of immediately available funds on the Firm Closing Date and (ii)&nbsp;with delivery of the Firm Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and
clear of all liens, with any transfer or stamp taxes duly paid by the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">II.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>The Option Investor Shares</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Underwriters exercise the Option, the Investor shall have the option to purchase, at the Purchase Price, a number of
Option Investor Shares from the Company, determined by multiplying 2,426,070 by a fraction, the numerator of which shall be the number of Option Shares as to which the Underwriters exercise the Option and the denominator of which shall be the
maximum number of Option Shares subject to the Option, rounded down to the nearest whole number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the sale of the Option
Investor Shares purchased pursuant to this Section II shall take place concurrently with the closing of the sale of the Option Shares, as to which the Underwriters exercise the Option (the &#147;<U>Option Closing Date</U>&#148;), (i) with payment
for the Option Investor Shares to be made to the Company by wire transfer of immediately available funds on the Option Closing Date and (ii)&nbsp;with delivery of the Option Investor Shares registered, as applicable, in the name of the Investor or
its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">III.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations, Warranties and Covenants</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants to and agrees with the Investor to all the same representations and warranties contained in
Section&nbsp;1 and the covenants contained in Section&nbsp;5 of the Underwriting Agreement <I>mutatis mutandis</I> to the same extent as if such representations and warranties and covenants were set forth herein for the benefit of the Investor
instead of the underwriters party to the Underwriting Agreement (except that references to the Underwriting Agreement therein shall be references to this Agreement and references to the Underwritten Securities and Option Securities thereunder shall
be references to the Firm Investor Shares and Option Investor Shares, respectively). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor hereby represents and warrants to the Company that it (i)&nbsp;is acquiring the
securities to be purchased pursuant to this Agreement (the &#147;<U>Purchased Securities</U>&#148;) for its own account solely for the purpose of investment and not with a view to, or for resale in connection with, any distribution of such Purchased
Securities or any interest therein and (ii)&nbsp;has been provided an opportunity to ask questions of and receive answers from representatives of the Company concerning the terms and conditions of this Agreement and the purchase of the Purchased
Securities contemplated hereby. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">IV.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Covenants of the Company</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company agrees to pay or
cause to be paid the reasonable fees and expenses of Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel to the Invus Entities, relating to the Public Offering and the transactions contemplated by this Agreement within 15 days of the submission of any
invoice with respect thereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">V.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Conditions to the Investor&#146;s Obligations to Purchase the Purchased Securities</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Investor hereunder to purchase the Firm Investor Shares and the Option Investor Shares, as the
case may be, from the Company, and of the Company to sell the Firm Investor Shares and the Option Investor Shares, as the case may be, to the Investor, will be subject to the satisfaction or waiver of the following conditions on or prior to the Firm
Closing Date and the Option Closing Date, as the case may be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The satisfaction by the Company of the conditions set forth in
Section&nbsp;6 of the Underwriting Agreement (other than clause (l)&nbsp;thereunder); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The substantially concurrent closing of the
sale of the Firm Shares and the Option Shares, as the case may be, on the terms set forth in the Underwriting Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The delivery
to the Investor of opinions of counsel to the Company by the same counsel as set forth in Sections 6(b), (c) and (d)&nbsp;of the Underwriting Agreement in the form and substance acceptable to the Investor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The delivery to the Investor of the officer&#146;s certificate contemplated by Section&nbsp;6(f) of the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These conditions are for the Investor&#146;s sole benefit and may be waived by the Investor in its sole discretion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">VI.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall automatically terminate upon any termination of the Underwriting Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">VII.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company hereby agrees to indemnify and hold harmless each of the Invus Entities and each of their respective affiliates, directors,
officers, agents and employees and each person, if any, who controls the Invus Entities within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the &#147;<U>Indemnitees</U>&#148;) from
and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any
of the transactions contemplated by this Agreement. For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be obligated to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease
in the trading price of their Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The provisions of Sections 13, 14, 17, 18 and 19 of the Underwriting Agreement are
incorporated herein by reference and shall apply to this Agreement <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement may not be amended or
modified except by an instrument in writing signed by, or on behalf of, the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement shall be deemed to satisfy
(i)&nbsp;any requirements of the Invus Entities, as applicable, to provide written notice to the Company in accordance with Section&nbsp;12.03 of the Certificate of Incorporation in order to be considered a &#147;Covered Stockholder&#148;, (ii) the
Company&#146;s obligations under the Certificate of Incorporation with respect to the delivery of a &#147;Notice of Issuance&#148; with respect to the Firm Shares and any Option Shares and (iii)&nbsp;the Company&#146;s obligations under the
Registration Rights Agreement to provide written notice of the Public Offering, and shall, to the extent the Company issues and delivers the Firm Shares and any Option Shares as contemplated by this Agreement, constitute the Invus Entities&#146;
waiver of rights pursuant to each of Section&nbsp;12.01 of the Certificate of Incorporation and Section&nbsp;2.02 of the Registration Rights Agreement, as applicable, with respect to the Firm Shares and the Option Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) This Agreement may be executed and delivered in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All notices and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon
receipt) by delivery in person, by fax, by electronic transmission, by a recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at
such other address for a party as shall be specified in a notice given in accordance with this clause (f)): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to any of
the Invus Entities: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Artal International S.C.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">44 rue de la Vall&eacute;e </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">L-2661</FONT> Luxembourg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Luxembourg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Anne Goffard </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Invus Group, L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">750 Lexington Avenue (30th Floor) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: David van Zandt </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with
a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Simpson Thacher&nbsp;&amp; Bartlett LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">425 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
New York 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Kenneth Wallach, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hui Lin, Esq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lexicon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2445 Technology Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;President and Chief Executive Officer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vinson&nbsp;&amp; Elkins L.L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">845 Texas Avenue, Suite 4700 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Houston, Texas 77002-6760 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: David Palmer Oelman, Esq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INVUS, L.P.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Bermuda limited
partnership</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Invus Advisors, L.L.C., its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CFO of the General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARTAL INTERNATIONAL S.C.A., a Luxembourg partnership limited by shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Artal International Management S.A., its managing partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARTAL GROUP S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">D&eacute;l&eacute;gu&eacute;e &agrave; la gestion journali&egrave;re</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARTAL INTERNATIONAL MANAGEMENT S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INVUS ADVISORS, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Purchase Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INVUS PUBLIC EQUITIES, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Invus Public Equities, LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMAURY WITTOUCK</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amaury Wittouck</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">STICHTING ADMINISTRATIEKANTOOR WESTEND</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amaury Wittouck</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amaury Wittouck</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sole Member of the Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WESTEND S.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Purchase Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and agreed to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LEXICON PHARMACEUTICALS, INC., a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Purchase Agreement </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>d342123dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B>EXECUTION VERSION<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PURCHASE AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;27,
2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Invus US Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">750 Lexington Avenue (30th
Floor) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Philip J.
Bafundo </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2445 Technology
Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn:&nbsp;President and Chief Executive Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to (a)&nbsp;that certain Underwriting Agreement being entered into by Lexicon Pharmaceuticals, Inc. (the
&#147;<U>Company</U>&#148;) with the representatives of the underwriters named in Schedule II thereto (the &#147;<U>Underwriters</U>&#148;) concurrently with this Agreement (the &#147;<U>Underwriting Agreement</U>&#148;) providing for the issuance
by the Company to the Underwriters (the &#147;<U>Public Offering</U>&#148;) of 16,843,600 shares (the &#147;<U>Firm Shares</U>&#148;) of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;), plus up to
2,526,540 additional shares of Common Stock (the &#147;<U>Option Shares</U>&#148;) that may be issued pursuant to the Underwriters&#146; option to purchase additional shares of Common Stock provided for in Section&nbsp;2(b) of the Underwriting
Agreement (the &#147;<U>Option</U>&#148;), for sale in a public offering at a price to the public of $2.50 per share (the &#147;<U>Purchase Price</U>&#148;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to
them in the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants and agreements herein contained, and intending to be legally
bound hereby, Invus US Partners LLC (the &#147;<U>Investor</U>&#148;) shall purchase, subject to the terms and conditions herein, (i) 982,600 shares of Common Stock (the &#147;<U>Firm Investor Shares</U>&#148;) and (ii)&nbsp;in the event that the
Underwriters exercise the Option, up to 147,390 shares of Common Stock (the &#147;<U>Option Investor Shares</U>&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>The Firm Investor Shares</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of the conditions described in Section V, the Investor hereby agrees to purchase the Firm Investor
Shares from the Company at the Purchase Price. The total purchase price for the Firm Investor Shares shall be equal to $2,456,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
closing of the sale of the Firm Investor Shares shall take place concurrently with the closing of the sale of the Firm Shares under the Underwriting Agreement (the &#147;<U>Firm Closing Date</U>&#148;), (i) with payment for the Firm Investor Shares
to be made to the Company by wire transfer of immediately available funds on the Firm Closing Date and (ii)&nbsp;with delivery of the Firm Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and
clear of all liens, with any transfer or stamp taxes duly paid by the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">II.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>The Option Investor Shares</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Underwriters exercise the Option, the Investor shall have the option to purchase, at the Purchase Price, a number of
Option Investor Shares from the Company, determined by multiplying 147,390 by a fraction, the numerator of which shall be the number of Option Shares as to which the Underwriters exercise the Option and the denominator of which shall be the maximum
number of Option Shares subject to the Option, rounded down to the nearest whole number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the sale of the Option Investor
Shares purchased pursuant to this Section II shall take place concurrently with the closing of the sale of the Option Shares, as to which the Underwriters exercise the Option (the &#147;<U>Option Closing Date</U>&#148;), (i) with payment for the
Option Investor Shares to be made to the Company by wire transfer of immediately available funds on the Option Closing Date and (ii)&nbsp;with delivery of the Option Investor Shares registered, as applicable, in the name of the Investor or its
designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">III.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations, Warranties and Covenants</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants to and agrees with the Investor to all the same representations and warranties contained in
Section&nbsp;1 and the covenants contained in Section&nbsp;5 of the Underwriting Agreement <I>mutatis mutandis</I> to the same extent as if such representations and warranties and covenants were set forth herein for the benefit of the Investor
instead of the underwriters party to the Underwriting Agreement (except that references to the Underwriting Agreement therein shall be references to this Agreement and references to the Underwritten Securities and Option Securities thereunder shall
be references to the Firm Investor Shares and Option Investor Shares, respectively). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor hereby represents and warrants to the
Company that it (i)&nbsp;is acquiring the securities to be purchased pursuant to this Agreement (the &#147;<U>Purchased Securities</U>&#148;) for its own account solely for the purpose of investment and not with a view to, or for resale in
connection with, any distribution of such Purchased Securities or any interest therein and (ii)&nbsp;has been provided an opportunity to ask questions of and receive answers from representatives of the Company concerning the terms and conditions of
this Agreement and the purchase of the Purchased Securities contemplated hereby. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">IV.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Covenants of the Company</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company agrees to pay or
cause to be paid the reasonable fees and expenses of Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel to the Investor, relating to the Public Offering and the transactions contemplated by this Agreement within 15 days of the submission of any
invoice with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">V.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Conditions to the Investor&#146;s Obligations to Purchase the Purchased Securities</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Investor hereunder to purchase the Firm Investor Shares and the Option Investor Shares, as the
case may be, from the Company, and of the Company to sell the Firm Investor Shares and the Option Investor Shares, as the case may be, to the Investor, will be subject to the satisfaction or waiver of the following conditions on or prior to the Firm
Closing Date and the Option Closing Date, as the case may be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The satisfaction by the Company of the conditions set forth in
Section&nbsp;6 of the Underwriting Agreement (other than clause (l)&nbsp;thereunder); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The substantially concurrent closing of the
sale of the Firm Shares and the Option Shares, as the case may be, on the terms set forth in the Underwriting Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The delivery
to the Investor of opinions of counsel to the Company by the same counsel as set forth in Sections 6(b), (c) and (d)&nbsp;of the Underwriting Agreement in the form and substance acceptable to the Investor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The delivery to the Investor of the officer&#146;s certificate contemplated by Section&nbsp;6(f) of the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These conditions are for the Investor&#146;s sole benefit and may be waived by the Investor in its sole discretion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">VI.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall automatically terminate upon any termination of the Underwriting Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">VII.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company hereby agrees to indemnify and hold harmless the Investor and each of its respective affiliates, directors, officers, agents
and employees and each person, if any, who controls the Investor within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the &#147;<U>Indemnitees</U>&#148;) from and against any and
all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any of the transactions
contemplated by this Agreement. For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be obligated to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease in the trading
price of their Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The provisions of Sections 13, 14, 17, 18 and 19 of the Underwriting Agreement are incorporated herein
by reference and shall apply to this Agreement <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement may not be amended or modified except by an
instrument in writing signed by, or on behalf of, the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement may be executed and delivered in one or more counterparts, and by the
different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) All notices and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon
receipt) by delivery in person, by fax, by electronic transmission, by a recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at
such other address for a party as shall be specified in a notice given in accordance with this clause (e)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Investor: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Invus Group, L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">750
Lexington Avenue (30th Floor) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: David van Zandt </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Simpson
Thacher&nbsp;&amp; Bartlett LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">425 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Kenneth Wallach, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hui Lin, Esq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lexicon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2445 Technology Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;President and Chief Executive Officer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vinson&nbsp;&amp; Elkins L.L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">845 Texas Avenue, Suite 4700 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Houston, Texas 77002-6760 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: David Palmer Oelman, Esq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INVUS US PARTNERS LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Bafundo</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Philip Bafundo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Person</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and agreed to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEXICON PHARMACEUTICALS, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President and Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Purchase Agreement </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d342123dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g342123g0728071748076.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>NEWS RELEASE</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON
ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Woodlands, Texas, July</B><B></B><B>&nbsp;27, 2022</B> &#150; Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX) (&#147;<B><I>Lexicon</I></B>&#148;) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001
(the &#147;<B><I>Common Stock</I></B>&#148;). In addition, Lexicon intends to grant the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase additional shares of Common Stock. There can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Citigroup and Piper Sandler are acting as joint
book-running managers for the proposed offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lexicon currently intends to use the net proceeds that it will receive from the
offering, together with its existing cash and cash equivalents and short-term investments, for (i)&nbsp;funding <FONT STYLE="white-space:nowrap">pre-commercial</FONT> and commercial launch activities for sotagliflozin in heart failure;
(ii)&nbsp;funding continued development of sotagliflozin in heart failure and LX9211 in neuropathic pain; and (iii)&nbsp;working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> relating to the proposed offering was filed with the U.S.
Securities and Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) on August&nbsp;6, 2021 and declared effective by the SEC on September&nbsp;14, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-258564).</FONT> A preliminary prospectus
supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC&#146;s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying
prospectus may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-831-9146,</FONT></FONT></FONT> or by email at prospectus@citi.com; or Piper Sandler&nbsp;&amp; Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attn: Prospectus Department, by telephone at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-747-3924,</FONT></FONT></FONT> or by email at prospectus@psc.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lexicon Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#146; lives. Through its Genome5000<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases.
Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising
drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as
amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without limitation, statements about the completion and timing of the offering and the grant of the option to the
underwriters to purchase additional shares, are based on management&#146;s current assumptions and expectations and involve risks, uncertainties and other important factors, including Lexicon&#146;s ability to meet its capital requirements,
successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it
obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#146;s actual results to be materially different from any future results expressed or implied by such forward-looking
statements. Information identifying such important factors is contained under &#147;Risk Factors&#148; in Lexicon&#146;s filings with the SEC, including its annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021, quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022 and other subsequent disclosure documents filed with the SEC. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of new information, future events or otherwise. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Kelly </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mkelly@lexpharma.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>d342123dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g342123g0728194849196.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>NEWS RELEASE </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON
ANNOUNCES PRICING OF $85.0 MILLION PUBLIC OFFERING AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCURRENT PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Woodlands, Texas, July</B><B></B><B>&nbsp;28, 2022 </B>&#150; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
(&#147;<B><I>Lexicon</I></B>&#148;) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the &#147;<B><I>Common Stock</I></B>&#148;). The shares of Common
Stock are being offered at a public offering price of $2.50 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be approximately $42.1&nbsp;million, before deducting underwriting
discounts and commissions and other offering expenses. In addition, Lexicon has granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 2,526,540 shares of Common Stock (the &#147;<B><I>Option
Shares</I></B>&#148;) at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about August&nbsp;1, 2022, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lexicon currently intends to use the net proceeds that it will receive from the public offering and the concurrent private placement, together
with its existing cash and cash equivalents and short-term investments, for (i)&nbsp;funding <FONT STYLE="white-space:nowrap">pre-commercial</FONT> and commercial launch activities for sotagliflozin in heart failure; (ii)&nbsp;funding continued
development of sotagliflozin in heart failure and LX9211 in neuropathic pain; and (iii)&nbsp;working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Citigroup and Piper Sandler are acting as joint book-running managers for the public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the shares being sold in the underwritten public offering, Lexicon has agreed to sell 17,156,400 shares of its Common Stock to
raise gross proceeds of approximately $42.9&nbsp;million in a concurrent private placement at $2.50 per share to one or more affiliates (the &#147;<B><I>Private Placement Purchasers</I></B>&#148;) of Invus, L.P., Lexicon&#146;s largest stockholder.
The Private Placement Purchasers will have the option to purchase, on a pro rata basis, up to an additional 2,573,460 shares of Common Stock at the public offering price of $2.50 per share to the extent the underwriters exercise their option to
purchase the Option Shares. The sale of these shares of Common Stock will not be registered under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;). The concurrent private placement is also scheduled to close on
August&nbsp;1, 2022, subject to the satisfaction of customary closing conditions. The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> relating to the underwritten public offering was filed with
the U.S. Securities and Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) on August&nbsp;6, 2021 and declared effective by the SEC on September&nbsp;14, 2021. The shares of Common Stock proposed to be issued in the concurrent private placement
have not been registered under the Securities Act, or the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
securities laws of any state or other jurisdiction in&nbsp;the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in&nbsp;the United
States&nbsp;except pursuant to registration under the Securities Act, or an applicable exemption from the registration requirements of the Securities Act and, in each case, in compliance with other applicable securities laws. A preliminary
prospectus supplement and accompanying prospectus relating to the underwritten public offering have been filed with the SEC and are available on the SEC&#146;s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be
filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-831-9146,</FONT></FONT></FONT> or by email at prospectus@citi.com; or Piper Sandler&nbsp;&amp; Co., 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, Attn: Prospectus Department, by telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-747-3924,</FONT></FONT></FONT> or by email at prospectus@psc.com.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any
sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lexicon Pharmaceuticals
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#146; lives. Through its
Genome5000<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of
diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of
promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This press
release contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without
limitation, statements about the completion and timing of the public offering and the concurrent private placement, are based on management&#146;s current assumptions and expectations and involve risks, uncertainties and other important factors,
including Lexicon&#146;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its
anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional
factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#146;s actual results to be materially different
from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#147;Risk Factors&#148; in Lexicon&#146;s filings with the SEC, including its annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March 31, 2022 and other subsequent disclosure documents filed with the
SEC. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Kelly </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mkelly@lexpharma.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>8
<FILENAME>d342123dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g342123g0728083921918.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>NEWS RELEASE</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON
ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR SOTAGLIFLOZIN TO TREAT HEART FAILURE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>NDA supported by <FONT
STYLE="white-space:nowrap">SOLOIST-WHF</FONT> and SCORED Global Phase 3 Program Evaluating Sotagliflozin </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>in Almost 12,000 People
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Woodlands, Texas, July</B><B></B><B>&nbsp;27, 2022</B> &#150; <U>Lexicon Pharmaceuticals, Inc</U>. (Nasdaq: LXRX) today
announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. The FDA assigned a
standard review for the NDA filing with a Prescription Drug User Fee Act (PDUFA) target action date in May 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;This is an
important step in potentially bringing sotagliflozin to market as a new treatment for heart failure,&#148; said Lonnel Coats, Lexicon&#146;s chief executive officer. &#147;Informed by our regulatory discussions, we are seeking a broad heart failure
label in the NDA encompassing heart failure patients with and without diabetes, and believe that the results of <FONT STYLE="white-space:nowrap">SOLOIST-WHF</FONT> in patients admitted for recent worsening heart failure will be an important element
distinguishing our proposed label. We look forward to engaging with the FDA during the review process to bring this potential new treatment to market by the middle of next year.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The NDA is supported by the results from the Phase 3 <FONT STYLE="white-space:nowrap">SOLOIST-WHF</FONT> clinical study in patients with type
2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease. In the NDA, Lexicon is seeking that
sotagliflozin be indicated to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in
adults with heart failure, including those with acute or worsening heart failure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reduce the risk of cardiovascular death, hospitalization for heart failure, urgent heart failure visit,
nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors, including a history of heart failure. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>About the <FONT STYLE="white-space:nowrap">SOLOIST-WHF</FONT> and SCORED Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SOLOIST-WHF</FONT> was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating
the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 people with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events
comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in people treated with sotagliflozin compared with placebo. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study
evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 people with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and
urgent visits for heart failure in people treated with sotagliflozin compared with placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Both
<FONT STYLE="white-space:nowrap">SOLOIST-WHF</FONT> and SCORED achieved their respective primary endpoints, with overall tolerability similar to placebo across both trials. Results from both studies were presented at the Late-Breaking Science
Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in <I>The New England Journal of Medicine (NEJM)</I> in two separate articles titled: &#147;Sotagliflozin in Patients with Diabetes and Recent
Worsening Heart Failure&#148; and &#147;Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>About Sotagliflozin
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Discovered using Lexicon&#146;s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible
for glucose regulation known as sodium-glucose <FONT STYLE="white-space:nowrap">co-transporter</FONT> types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose
reabsorption by the kidney. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, type 1 and type 2 diabetes, and chronic kidney disease in fourteen Phase 3 clinical studies involving approximately 20,000
patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>About Lexicon Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#146; lives. Through its Genome5000<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases.
Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising
drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit <U>www.lexpharma.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This press release contains &#147;forward-looking statements,&#148; within the meaning of the federal securities laws, including, but not
limited to, statements relating to the timing, clinical development of, regulatory filings and proposed label for, and potential therapeutic and commercial potential of sotagliflozin. All forward-looking statements are based on management&#146;s
current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#146;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain
necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well
as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#146;s actual results to be
materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#147;Risk Factors&#148; in Lexicon&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022 and other subsequent disclosure documents filed with
the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Kelly </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mkelly@lexpharma.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>lxrx-20220727.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 7/30/2022 1:10:51 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:lxrx="http://www.lexpharma.com/20220727"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.lexpharma.com/20220727"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220727_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220727_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lxrx-20220727_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 7/30/2022 1:10:51 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lxrx-20220727_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 7/30/2022 1:10:51 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lxrx-20220727.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g342123g0728071748076.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342123g0728071748076.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +D# 2(  A$! Q$!_\0
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M^J]@\TFGVTEPFR=HE,B 8VMCD58H **** "D(# @C(/4&EHH :B)&@1%"JO
M ' ID]M%<JBRKN".LB\]&4Y!J6B@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g342123g0728083921918.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342123g0728083921918.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +D# 2(  A$! Q$!_\0
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g342123g0728194849196.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342123g0728194849196.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +D# 2(  A$! Q$!_\0
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M^J]@\TFGVTEPFR=HE,B 8VMCD58H **** "D(# @C(/4&EHH :B)&@1%"JO
M ' ID]M%<JBRKN".LB\]&4Y!J6B@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g342123g0729025542233.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342123g0729025542233.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 *H# 2(  A$! Q$!_\0
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MX?$>E-C;"EI/:N,K*@ "G/8@ <X/2K$,\FL0)XLF""6T0QVEL1E(F8@,Y/\
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+M;J%)*=^;6Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g342123g0729025542389.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g342123g0729025542389.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 #0# 2(  A$! Q$!_\0
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LT452UT(EIJBO<:=<>)IVU"_NHO-X15C@P%4#IRQ[D_G1111S-:(%!/5G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140295147642032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 27,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d342123d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20220727.xsd" xlink:type="simple"/>
    <context id="duration_2022-07-27_to_2022-07-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-07-27_to_2022-07-27">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-07-27_to_2022-07-27"
      id="Hidden_dei_EntityCentralIndexKey">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-07-27_to_2022-07-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-07-27_to_2022-07-27">2022-07-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-07-27_to_2022-07-27">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-07-27_to_2022-07-27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-07-27_to_2022-07-27">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-07-27_to_2022-07-27">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-07-27_to_2022-07-27">2445 Technology Forest Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-07-27_to_2022-07-27">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-07-27_to_2022-07-27">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-07-27_to_2022-07-27">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-07-27_to_2022-07-27">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-07-27_to_2022-07-27">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-07-27_to_2022-07-27">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="duration_2022-07-27_to_2022-07-27">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-07-27_to_2022-07-27">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-07-27_to_2022-07-27">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="duration_2022-07-27_to_2022-07-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-07-27_to_2022-07-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-07-27_to_2022-07-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-07-27_to_2022-07-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-07-27_to_2022-07-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/UY_ 5!+ 0(4 Q0    ( $.*_50'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 0XK]5#G/M6+O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ 0XK]5)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !#BOU46)FY]&H$   ^$0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ 0XK]5)^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !#BOU4EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " !#BOU4'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ 0XK]5"0>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 0XK]5&60>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d342123d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d342123d8k.htm">d342123d8k.htm</File>
    <File>d342123dex101.htm</File>
    <File>d342123dex102.htm</File>
    <File>d342123dex11.htm</File>
    <File>d342123dex51.htm</File>
    <File>d342123dex991.htm</File>
    <File>d342123dex992.htm</File>
    <File>d342123dex993.htm</File>
    <File>lxrx-20220727.xsd</File>
    <File>lxrx-20220727_lab.xml</File>
    <File>lxrx-20220727_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>24
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d342123d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d342123d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20220727_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20220727_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20220727.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20220727",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d342123d8k.htm",
      "contextRef": "duration_2022-07-27_to_2022-07-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d342123d8k.htm",
      "contextRef": "duration_2022-07-27_to_2022-07-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001193125-22-206851-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-206851-xbrl.zip
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M2Q<H,NU"ESYUKER+37YGTU)B2 4%UAQ: V2G<6 <&49V?/4YROALP'S084S
M,XIR1TB)@[Z(U (=U"#O2L(>>PXRCOQNY.-04-*KD3S7)L**7E/?]#DNT<I*
MXQG4T=EI/3T?/?O4C.6SX*&O'J4 =32YY>JM0.ZH&I.+%S_:%GXQL)E/Y!!8
MKGAWKWY/+]A\91QU;OL>K"BWXD>0;#^XH $[FXTMJCE[-QNK55 V>A-W&_=3
M3U$GIN:,>O6D!-9!4N&_A+QBK2IU[*';,6$NS"^EWS_:5C#J'-7V;?<D4=9A
M@^!D3/VA[5;Q<X?0,.#1-[X]'.FOL#DO:@R59G7$Y%NPTU[<1,"]3N*QSX.
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M 98?,?.;Q&G4 Y\7W#F,"?;YA/29PQ^)K4#<!YCF<I]&9K[(29"![2!VMP4
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M,C$R,V1E>#$P,2YH=&WM76ES6KG2_DX5_T'EF4DY5<3!CK>Q':HP)C8S>+F
MXYG[UOM!@ #=G(4YBY?[ZV]W2SH;!VR\8"<A-9.8PY'4:K6>7B4?G'1.FY6#
MDWKUJ%(L''0:G6:]4O_KPWIY;?W@H_H(SS_J%]C!X?G1W^SPN';>/&]]7KDZ
M:73J*Q56+,!+->$$PJL<'#6^LG;G[V;]\\J-[ >CO=VU+>FL,&[)H?-YQ1*#
M8(7ZNC"OV=P;2N=#X([WRN-@G^G/73<(7%L]&KA.\,&7_Q5[Z_'G ;>E=;?7
MD;;PV9FX82W7YC!2M=DX/ON\XLGA"(8Z.*S4;T>R*P.&TV(''P\K!Q\O<%YY
M%*QO/#\)];_JM<M.X_R,?:VWVO@O$I#/@6<=OT=K0CPXN*Q<7+9J)]5VO5BH
M'K?J]=/Z60<(N:P8CDPA:/<9"*K\$5IW[YRN/][?V"FQC?+&QDOSH%+U FZQ
M!G+ X8%T'6X5"^VUVEIU;<;8SR&!E<U-YH6"]06S./O*+>N=X+TP$/OBI4<^
M^'(.JPKSU#MP) /QP1_SGMASW!N/CU<JS0\;V]NPO?'-"FN&M\+NNJ$W?&G2
M,B--V7_/,E0U"$#R8<GW6-5Q!#MV!P/N]5]<Y#HC 0)W'?KLV'/#<8DUUYH@
M<"\^WYVM,FN*6^D, ]=AU6OA@/2M?BH'(_;%<EWO_4NO+?[XM^M]*S'S$X"M
MV>0+6NDC?BW[[)H[[-_<Z0<OOMC(\!ZP^V+$/1LV6!C('K?\$DA [^67?&-S
M<XMU1&_DN)8[O&-?7$_X 3NTKOMK);:^?M"^C,:..][9^FV?70N/2/U *GD/
M2%JI!*.#C]"BHN3EQ:G'C7+ENGT+5@HXUA&WW&<[.Y]VUU]:4D%@G#VEB2Z
M8[(/XL. "E8;23$H%NJW I!:7@MV/AC(GO!>7HYX7\(3I.$8B+&$+4":9ZS
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M-*)R/VG08B%GU"GN6:+'S%=@6PA_C))P#6I%!]+0#P(O*+]H8&+SL.1NV<T
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M]&&^BT%>93AS%$Y\%LTG^4A=!HEKU&IMP7!GL%M>G[0+8Y"UK?E23M^Z/5\
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MJ/Q3JJ.9<!:*7,X<0R!5".-8P"%-0'U>5 IV@P 1! ZQM!%1W :T*"P \@:
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M&X&;ZLSX&#RBU\<GQ\\/R9P7U.&6#>QZ*RRX_[@J?YKWQ;5J_^Z!YN$0"0F
M",*C]Q3:!/]AF./ZN^9Z#O_IN1X<F'T5X:RNEB]WY<MANH*%T*2J9ELMQ]7P
M6*JTICL*D]+9R:N2JC@E-W1%3.%\AC ],#O_[8&^3B6KV4[Z"$M*>&S-(^2
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MV-/5(AW72UC"Y6(QT\?/$IH&V;->FE'4:M!!<%>4>;==S!5XZS>?8-OG9Z1
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M$[!/QB22L3?L15ZKY0B4:$Y[4#R/2D-8*,GM+;S&2@/]$C<D-B]JS/C"AJ%
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M47O'#29OF=<E;"(/3,"=ZV=GFHQI6HMY5@\'&"2K.86[:ESCG#Z.$--E?A?
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MQ#M'%U$NR\K DU2:I$P:\$BN@$T;#97@G<9)=8XV_56E&!NM:3 (A3U8+RR
MZ!(?']!PS'X=L$9P3["S$:[S&&VV=&(UJ. N"/.P8'PQVEN*$L1%4%!162S/
MN!;FW$,ILORRF%VFGDV-<KM4P>(Y+:5"7\SBP%1PU<"<K";7*'&!CX2@^?^
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M4;[_>9$S#O1NRAU<IU; C]WH)(/F]SC^)D*_6470J!$0OD"& #AHO-0-N'Z
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M]B_J+'3OV)T6E\55FW4 FDVE.K2J:)=8'S_&+#I6\Z5)+>2P8-@Q'UU6@4Y
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M$;1H,"VF4PF2?5PJ?L"/9F/?JH?[#R;)2AM7B4IFWC[JXGR5H,YF#UQ4)7-
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MHXML?#%*;%]TO0GXCBU9W ;TO&WLLDE(D5@_Z](PTHHST,W TA,9QJ6,7+^
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MAVPA/>-!^ 2]PU=K7R6FRR!>Z:Q"XX+]KZ(,EI70W"9O[EZ&0$ L-$E5PWR
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M'>X?//G^R=,?/%XAC#EN]1 E*?C]K_0,5Y=!4XS9D)J;</"$T!SLA+VLO]H
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MM/Y1_6\J_K$=1E;I.(V#U;L!3"2'Z60F?RRKVL515\4290G^ P?ZJ"IF"&1
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M__DQ AH')?$,V<F+RR]7M>;4D8TV(FRK)*8PD :I'?7Z!4!3!T*S'"+_SR8
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M!J.>#=MF#-->+AUU,46"]89%1&QOS(?YG)^5S]G$5JS-)=F<"=434#%E,1=
M33',K-9O%KU<$>YR?6=#9AN[@)<[0&QA5^P[8,N2\('(1(J?P/\)('.@>-B,
MAR0 L8O07HHI>\33U.0UD/P93[F:UH@9 *V6G5X :,$2T^P^3 Q>!R!M#!-4
MG2!IQ 74(S; OOR-D/YXF\-DF12I1!H%$!;PM7N0SW6/>2@EF#ACTCM7H'@>
M4!>SL^MO[LHEU7C^1BF;XDMEX+B=GW??$'KW+7&DVN)G/FX(QX8KU::YO22B
M*0'I&;RB$8\/P<S$!H>0.9XS42SY!Q!;#G^E%WH2ZY?F#"I=8=( E;W*@F2=
M5V*:[[V!@5BGJ:P92I=7+B%.<D9M#I%JB5XM?@;UXYI8P('H<G0K#A04^;\S
MP&'#I80!Q<E-.#"TK5&&:<(*%Y!R?:PA;=/2=GJ>6&5C>^ (':\=W8E)$GXV
M%Q\B-RO6'YI<B)9$26KR_ (0?J^7W%BR3"!TNK(>=G2@P;<074YH*P0#UMC?
M)IR@J<)&"+E:#T,<O [3F@.<XR  CDHPB2R8RLJ:UJA"&0ME81+E2%WI.N\:
M1V0#0!%"XXB6NA\Y@.&MR#IL+H=]8+#AAJS=H. '%>]Z%.L/[Z)>)@RH6!QM
M!'%:BHG<)B%)$1-]^NF Y:NLC9H4 V2<Y"HF)&C#ELB_<!W>.*#E,G3;B,<W
M\@S3)9L<+HH\TS![[27(/K/Q5EE+Q%Y/NA+LVZ!G $%A4%)7DKK$3B\"(N34
M^Q8D>D,)>1)V/M=3PY:Y"7I^*?(U<M@2!.%HU8(:FOEK\$GZ0XF\VZ>(,.!>
M$[^'@::O&AI0C;(WE-C&YHXHZ^LT79 'A-A&"%C;@3^A8:(8>#QN).R#X **
MZ:"'Z+7\N6J1/K:-?>ML09/0H'[F QHP6PG/IR_=+5H;9(L,E F-&,1EY""*
MRT;AS3,=%0"0WC(-%HR0N;>Q\[1#\L:T:U :J!-Z[*+CZTA]#HL616ZA@0RJ
M'?4]P+H7\QQVQ?&^[O,+?;A($[:S5/($S_=2?EK\+DGFP9SHH_5[&T"Y7>+2
M$@J+P\=Q"GM'[(QTJ#[HYO6MZ&Y0F!\@\Q0.BH\T%;1C%>6#]5UD5Q-K A1A
M!'><*KI20/X/:;2$@>SQZIC:GG<*=Q_9V\.$N1E+^A#3&PTGWE63(&PEMS S
M:$#%ZN->Z+6!&GZ(ASYB>NINFU.GFZ7Z>*.#"QI,;HN"*1J0<H-MATP[$E-8
MK%&WL$;M(2&O:TAD^#IL#B!<D%O0)<,3_]89_E)NSRA-RQXQ=H@VGC /;8]$
M";1%OT)&9@)[35ZO$%VFX?E1/PBL;P?2!I0PK]+D%$L[T:_LV;E,S^!9:$-@
M+"6'AX?2Y10I L(:V*X61T_9L)7QX^9]L@DST#9GP)W15D0.^2@F3A?QL\^P
MRV'?<.ML'Z%<M[A36IV5-8I68(]F\_&%M%Z;QUX"A<YA<B.)8T!A$'4'GB_F
M)!INZ#@G=+N]M[E3]$(M8UO&Z_3BC9JB7X0=5+8K*/@!7?0CCN;P0Z6-6SIZ
M 9,H'-5@@ >=C@YHT'\Z/A6S,D<EA=Z(,G&(2G!^2_+R4P38RM=>+$E4B@NE
M)Z!$AI :H."SM%%'%R(U.2?>LB?FG2ETV6]8X.#]8I(\:4,BF#R.P]-\4>CR
M>L[?F;!N$2S/!T;&%**Z,6YX/[R+XH[TB?D^+G_F!YV8U%D2B"."WJ04RP@%
M2Y?BYG,:D:D!N8IX"?3,"0&>4<AP:JA;4N60-6+($3,6] (O1KWJ$^BV4K!1
M*K8&\@P1]3A\RG?8F0;$#[4%I&(57> I S@#><H5U;0D1<P?G10D$CH:>P:D
M;DXRB#(,J87]0&A&L%*%]O:@C:Y'H9A;#LFT8SHOD9,H43RN>C='LQ&H3>7N
M-(30^#0OQ3"R0=Q4$B6MK,T3)C6(H%QS\RTV,*U] C'OWE<*G?K!+33013(C
M[=1H^O><[T,3$UOWT:4[,*,A_>!X(#5((2QK:7I))-='DMP@BY-TU?HI!<Z$
M,3G0YT.HJ1,2[>'D^-74TT35!LW+P0.MH,$@;YX[.>&1C8V8(3Y5,+9T.Q#F
ML.5RZ6 =L/[&1$.^ DJ+5L[1L-D"B>M><YOUD;-E!+<:LP6!WB39]CV#-QWU
M-!,V0T1 'IP<X_6!\TPNK=F?HI=NF9=\QI6R:VEZ0"MSY"7(+)=D/4P(,O,<
M*GT7W>.L3ZR 70E,[4HFR"@6SD3J?2.69M7S!*CR)G14,1J4]52''YCJM]!E
M2:3B#2#-&X.*+FX9SIR-6D/(BX&>\WJ@YZYOBLN(>3NVO#IB.WLA4GLR":9S
M#*Q(#9.I&NLB3ZX^@;7.U<*)7E7)GB==)&I%C'489:,X#'5 N- [< 3!-F3.
M0"\O:-PP1&JLW"/E U56#@T*SDCQWO64TD>[ ^(AS/R:ZQ/S(=Y0E!UMW_1&
MAGOSDV /&ZDZ4LK,0)0]N[X.DA'TUV$B!TD656ZDS[<\NK;YPANW.-5M*9@Y
M2*L&?I</],K:"/(J<8(-X5&U3R<16 GK'*BEP#(OTDMAGE9\%G1NHJ=!.559
M&\,YY:R.<BJWR#1(+Q.->UAX TD]U%:(,E%VWJEYL;\E=#/P__B5M6XL%@2/
M0>&37C/=L6(X=AVF^1&GDW!+0M19PKSK",-/8I!@G8I*>W(<O9.9>;X1!383
M#@$C@8EKB6]%I]B,0YLX&KL,I.%BZG7TFRMKZRQKPB9EY2\10F35B>2?R^([
M$ 8YS^*1#>Z8FGKJC?[=YS(+/(N&.%24)1V ,SF!K8BSA*=)U1*@W[UKS&ZN
M",R=Y(D0ZRWYKYI,V8X.T#-$_%1H'W+K-(.N'M@4Z^PZD@-W2 MIG+%4NR.)
M$8LRL *ZV;Q=Q<5&BL2*C"HN-$G4V HV&Q!).H/H'G:1)$TF198)G89^DUVL
M9]N,1*$(_HC!VJ!Y*\GIEYR@DE6+]VHN6,ZF9P?X?",0"2BZ@M"[>"B"RJ8X
M=P4 >XGT\V6IC)6L28DBM+E0W7%DJ"A89%2.)4-]SK;5=T^T]YS)VM[.R8'Q
M<_6[XFH[>!AL=^[N^BPC,5XS&WCRJO PK D"Z&(#II#SS,YZ4YR10%4,Y9&
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M6G*4)-8\KE:?&26*?4GP4+%P#'[U9W8=XGLJ' .7_K-6.:XU*L=')Y5ZG:#
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MFI#_T)E "I5A953Y7U/I3ZN3M<?18/C(A(AI\[KW"8OF?RS]%U!+ P04
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MY(N F1DW#)DYXYKY:CX7]BF/6!H%(EDFTA@1L3@=A])G:C(1B8RF.,5]QL*
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M3HT-L@GB6[S:H/E-J,;(F5M;Z+4E(Y#B0+&WB>)!(@-$R34DB"Q8#$6RD+X
M(M5J1T>LIV"=KB96Q-H+@>3W6 <[EJ!*'NM_PBI0;UO?*"!$*.*9BJP5ONKT
M/[@ L?W\DEKYI%HMGS1JY5.XP<M"9O=7)IR8PP<DV,9^__1AI0IL>TYK=DJ>
M"\>?^#P^1P[!8KB']5%.0E1T&)-HU,^U^K#:\-BMC"+!8Q5*G7TA0&1'1X?5
MNL?:QD1G[&[CM"L![F1QWWO&:"^J_.?MZHQV?'A<;IS6#_]KH\7:)YO]#9 [
MFDE-*:-M3@OB<H'"ED@9*DY895)*P2ACO,AW1W@S3J+A(KC<034R<'OA.%UY
MM AGZC66>C@Z<>EO+",D$(A63*.B$QUXM($*G%U =8"N_8P7.I"^O1(OX0_4
M8IWBA[W:VQ,JL6<SZ91"0,Z)U0<ODJ>3;]1"ML<J-6LNOM?&K!NS9SS^YGLR
M.$G$?RQ5O",3RU#1 39G>:&#7V+\%AD9%S _@#%C=ZC4D9Y0908'D42^'(*S
M$%5-$_,':DX=I[L1D9J+HVJUVAR^O]NDY4:GXZ,?S]E")%:>LIW:G,$:)2JJ
M1XWSY@'VM2AYT,[,-WV.]NEFT 9 O4D#:9L[P1(5.K8$QN7G00IH24!=CSR(
M81F0J_ RH!,FM'6N$N*RB.8:EN R(Q!I!KX@P+?&T1 ,B_VLIP(,6!NR&&MQ
M#&Q)@<L2RQEP:2 UI9<&L\@-DI4K7Q)QMF>3==<YD%VKMYHYO>T&VHY3?05K
MK3)2L4,B@9MJP2VWV'(9,IA/1.AVK-D'OIM$P)N9G)7UI3Q8<-L6$Z"NA=LY
M<*OEI4Z:0\H85=BMAQH((UMG@R0E$@KN&R"9;6KO*N!CDXU#^D*FR;]O:[;/
MAKU'!-C#L7PL3.;8N3!\3+5DOL5\):3P+41LJ.[!5?=79&0V2BP6F/W?C!%2
MJU#L0H28/TI.>A2C9RN/8<F'\E@@*<09#Y=\I6ENUGQWSX;=?R/<&Z7\2#O*
M//OAU/XKL0_=J]&[BQ*B[L=U[EYV^J/._?_=G)/P;8A(8N]X,@;*#M=$_>_
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M+]?K=1:;#L"GH?S7LB];>\:)A)YPK\B/E:1<'A(S1:LBFXJR< Q# %NH)Y"
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M7(J9P#)H4<-6J-R&SJ:&XV:.[I97:&M>X,MR38WU7&#$-6-_?;[Y&GHN.O<
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M9MN#W-T,![Z]:A<._?P!4$L#!!0    ( $.*_511O$^3>08  +I&   5
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MKF\'#\0G\RQ+=2<(ELME(YXRH25?9!A2-R*9!,3W;?_^^!/Y;3U<APR! ]5
M$JHS4.27!>-QI]5LM9IA>-8(6]LZ!=0$)#'-H$/.@W8S,#U)V F;G;.0].[)
M31%&D#%+8%LJTY5BLWE&OH]^((7H6@H!G,.*W#)!1<0H)R-K^4<R$%&#]#@G
M0R/3Z%.#>H:XL8G*F?BK8_Y-C'OR]@W!/TRDT$5KUS/IV&0CGRC>D&J&;IOM
MP(J\;4V^)UJV"TEX<7$1%%?+_36KZHT#A,$?]W>C: X)]1$"0HMVAD(W<?:/
M>MO<6;"^:/MKUM%%I#L9%:D_8EKD8 _SR;?=?-/DARV_'39R'7M79LAU5I7D
M,(0I,:^?AH/2F!SR=$Y50HM%5>!OGK?.@XSF4LAD%1A1<"VC10(BLZ\]$=^(
MC&6K@9A*%)NI>*3(:F>N8-KU>*YRWT8SAMX-,=#G4P)EJQ3O#,V2E(-'@JT)
MI0H7C\B*WG?84!) GH&((;9AS 3^JRE?K;EN%J^,2BFP]V\!34/4F,GG( 9F
M1@S-&Y.? M8[_/"Y+W'+Z$UTIFB4E7/ S6J1RC9R.@'>]2I$P;<TU,-IQV;J
MMYS.CC6T(RH;VN;64U$I)%61#8=O]Z"55_ZF1Y!2A?'\:(Z;G%5/E4PJD[,9
M358:E2H&U?5:K0;>\1Y)%9,*86.+1Q8:O<C4N*;<7(,I* 7QW7K:!UT6%G'W
MU%#T_,9XUJNQCS-0E ]PQ>>_PNI83 ?$]<5UP+#%UG8&F]U/QIC&8VF5-?6%
M5/9IV9PYQ^8)T"MN]_$U?C$Z%=*.N/ZT=@Q;;#\Y@VV]-PQAQLQ$1?9 DZ.I
M56OK"ZW:KV5V[A@S/!1(E4I5I':$&8:^7. 6O^K+^$2$7PA5=Z)?L&\!_^P8
MX%O&X6&13$"=1G-;5W=TVUXMIPO'.(UI/H@Q#6S*U@?3UT [&*3N! \:W^!L
M-QW#V8MC3++>O. 1&<+34%8&J#O&2M,68>@\PM;7(FRYB+#U+T+7SN:;6?3Q
M[:,:RZ5X%<!MN2/XMBU;>.Z<T$M3*;Z*/:HG)9^9*?R^AN!>#$<P[OFV+-^[
MR?))ZHSR/UEZ^NFB.H(C''=<6XKNU&7,?M)30$_A5M;4EU39IV7C3O'%_)+%
MG^92G'C.V]?5E]&^5\O)G8++"**%L1BV)F.6\:/OHWU=?3GM>[6<W*F;C!4U
M#PJ,5LE$\F,A[8CJ2VC'J,7C3KG$+K&;/)I3,8-3:LW5VOK"JO:[8?;>G9K(
M[^@O ]&72;(0FPJ//A;: 7%]J1TP;+&Y4P<92<XBEN%V<8_G$,7HT=MAE;*^
MP*K<6EKNE#R>%)@E!WA0+'X"-L_@J,?I]/AOA"]%J"^]EUQ;BN[4/G9F,]!Z
M >KK65;$<89HA7?+U;4ZR$T":H;[S$<EE]D<)YE2<>(C0P="U)?FB[8MR/^A
M%'(9[*7F#AO,HZ_K*^:?>9 36_X&4$L! A0#%     @ 0XK]5)*P4+M\&
M?:4   X              ( !     &0S-#(Q,C-D.&LN:'1M4$L! A0#%
M  @ 0XK]5")2\4:0%@  -Y4  !$              ( !J!@  &0S-#(Q,C-D
M97@Q,#$N:'1M4$L! A0#%     @ 0XK]5//>02M$$@  IE\  !$
M     ( !9R\  &0S-#(Q,C-D97@Q,#(N:'1M4$L! A0#%     @ 0XK]5#BV
M3W6=C   N\T" !               ( !VD$  &0S-#(Q,C-D97@Q,2YH=&U0
M2P$"% ,4    " !#BOU4[16^:6D*  "X)   $               @ &ES@
M9#,T,C$R,V1E>#4Q+FAT;5!+ 0(4 Q0    ( $.*_51F8G&MC0L  .X?   1
M              "  3S9  !D,S0R,3(S9&5X.3DQ+FAT;5!+ 0(4 Q0    (
M $.*_52[\#DK+ X  /@K   1              "  ?CD  !D,S0R,3(S9&5X
M.3DR+FAT;5!+ 0(4 Q0    ( $.*_53L]Y1HJ@X  / P   1
M  "  5/S  !D,S0R,3(S9&5X.3DS+FAT;5!+ 0(4 Q0    ( $.*_51DLCH9
M1 ,  %8+   1              "  2P" 0!L>')X+3(P,C(P-S(W+GAS9%!+
M 0(4 Q0    ( $.*_511O$^3>08  +I&   5              "  9\% 0!L
M>')X+3(P,C(P-S(W7VQA8BYX;6Q02P$"% ,4    " !#BOU4FYAK'<$$  !"
M+   %0              @ %+# $ ;'AR>"TR,#(R,#<R-U]P<F4N>&UL4$L%
3!@     +  L N (  #\1 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
